

# Gilles A Salles

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6961003/publications.pdf>

Version: 2024-02-01

904  
papers

59,413  
citations

1099

112  
h-index

1424

221  
g-index

935  
all docs

935  
docs citations

935  
times ranked

35215  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. <i>Journal of Clinical Oncology</i> , 2023, 41, 541-554.	1.6	23
2	Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2â€™Technical). <i>Journal of Nuclear Medicine</i> , 2023, 64, 239-243.	5.0	2
3	Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1â€™Clinical). <i>Journal of Nuclear Medicine</i> , 2023, 64, 102-108.	5.0	14
4	Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 975-984.	2.5	12
5	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas. <i>American Journal of Surgical Pathology</i> , 2022, 46, 58-70.	3.7	12
6	Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma. <i>Haematologica</i> , 2022, 107, 1144-1152.	3.5	6
7	Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. <i>Clinical Cancer Research</i> , 2022, 28, 45-56.	7.0	13
8	Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study. <i>Leukemia and Lymphoma</i> , 2022, 63, 599-607.	1.3	0
9	Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. <i>Blood Advances</i> , 2022, 6, 533-543.	5.2	77
10	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	1.4	49
11	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. <i>Cancer Medicine</i> , 2022, 11, 61-73.	2.8	4
12	Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program. <i>Cancers</i> , 2022, 14, 660.	3.7	3
13	Prospects in the management of patients with follicular lymphoma beyond first-line therapy. <i>Haematologica</i> , 2022, 107, 19-34.	3.5	13
14	Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 2536-2547.	5.2	8
15	Indolent lymphomas: introduction to a series highlighting progress and ongoing challenges. <i>Haematologica</i> , 2022, 107, 4-6.	3.5	3
16	Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 91-103.	10.7	236
17	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 351-363.	27.0	278
18	The upper ECHELON against T-cell lymphoma. <i>Annals of Oncology</i> , 2022, 33, 239-241.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 369-381.	1.6	60
20	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, 29.	6.2	1
21	A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma. <i>Blood Advances</i> , 2022, , .	5.2	3
22	Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group. <i>Cancers</i> , 2022, 14, 1761.	3.7	0
23	Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. <i>Blood</i> , 2022, 139, 1684-1693.	1.4	56
24	Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study. <i>Blood</i> , 2022, 139, 2338-2346.	1.4	18
25	CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2022, 63, 751-754.	1.3	10
26	PET-CT before autologous stem cell transplant in follicular lymphoma: coming too late?. <i>Haematologica</i> , 2022, , .	3.5	0
27	The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , 2022, 6, e726.	2.7	1
28	Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England. <i>Journal of Medical Economics</i> , 2022, 25, 730-740.	2.1	2
29	Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7560-7560.	1.6	0
30	A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL). <i>HemaSphere</i> , 2022, 6, e745.	2.7	7
31	Abstract 5186: Higher levels of circulating exhausted T-cells at pre- and post-infusion negatively associated with clinical efficacy in tisagenlecleucel (Tisa-cel) treated relapsed/refractory large B-cell lymphoma (r/r LBCL) patients (pts) in JULIET trial. <i>Cancer Research</i> , 2022, 82, 5186-5186.	0.9	0
32	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. <i>Clinical Cancer Research</i> , 2022, 28, 4003-4017.	7.0	15
33	Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas. <i>Blood Reviews</i> , 2022, 56, 100988.	5.7	6
34	A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial. <i>Blood</i> , 2021, 137, 1019-1023.	1.4	10
35	BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 267-278.e10.	0.4	8
36	No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib. <i>Leukemia and Lymphoma</i> , 2021, 62, 837-845.	1.3	1

#	ARTICLE	IF	CITATIONS
37	Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. <i>Leukemia and Lymphoma</i> , 2021, 62, 1077-1087.	1.3	13
38	A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2021, 137, 600-609.	1.4	79
39	Mutational landscape of gray zone lymphoma. <i>Blood</i> , 2021, 137, 1765-1776.	1.4	60
40	Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 1597-1609.	7.2	15
41	The use of tafasitamab in diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110274.	2.5	6
42	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217.		0
43	The role of tazemetostat in relapsed/refractory follicular lymphoma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110158.	2.5	11
44	Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 455-463.	3.1	24
45	Real-life targeted next-generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network. <i>British Journal of Haematology</i> , 2021, 193, 1110-1122.	2.5	8
46	Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2021, 384, 842-858.	27.0	388
47	Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. <i>Blood Advances</i> , 2021, 5, 1737-1745.	5.2	4
48	Immunosuppression medication adherence after allogeneic hematopoietic stem cell transplant: Impact of a specialized clinical pharmacy program. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110001.	0.9	7
49	A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the REAL world data in Lymphoma and survival in adults (REALYSA) cohort. <i>BMC Public Health</i> , 2021, 21, 432.	2.9	9
50	Relapsed/Refractory International Prognostic Index (R <sup>2</sup> -IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2021, 96, 599-605.	4.1	8
51	Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival. <i>Blood Advances</i> , 2021, 5, 1729-1732.	5.2	6
52	Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. <i>Journal of Clinical Oncology</i> , 2021, 39, 1203-1213.	1.6	39
53	Diffuse large B-cell lymphoma: new targets and novel therapies. <i>Blood Cancer Journal</i> , 2021, 11, 68.	6.2	41
54	Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20-containing chemoimmunotherapy (POD24).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7515-7515.	1.6	11

#	ARTICLE	IF	CITATIONS
55	Obinutuzumab (G)-atezolizumab (atezo)-lenalidomide (len) for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL): Final analysis of a phase Ib/II trial.. Journal of Clinical Oncology, 2021, 39, 7511-7511.	1.6	2
56	Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. Lancet Haematology, 2021, 8, e355-e364.	4.6	43
57	Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma. Blood, 2021, 137, 2704-2707.	1.4	21
58	Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1. Advances in Therapy, 2021, 38, 3266-3280.	2.9	10
59	CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood, 2021, 138, 2499-2513.	1.4	160
60	Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry. Cytotherapy, 2021, 23, 483-487.	0.7	8
61	Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. Journal of Clinical Oncology, 2021, 39, 1959-1970.	1.6	228
62	Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells. Clinical Nuclear Medicine, 2021, 46, 627-634.	1.3	25
63	Adverse outcome in follicular lymphoma is associated with <i>MYC</i> rearrangements but not <i>MYC</i> extra copies. British Journal of Haematology, 2021, 194, 382-392.	2.5	5
64	EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma. Future Oncology, 2021, 17, 2127-2140.	2.4	20
65	Optimizing CAR T cell therapy in lymphoma. Hematological Oncology, 2021, 39, 104-112.	1.7	10
66	Characteristics of T- and NK-cell Lymphomas After Renal Transplantation: A French National Multicentric Cohort Study. Transplantation, 2021, 105, 1858-1868.	1.0	3
67	Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming. Journal of Clinical Investigation, 2021, 131, .	8.2	4
68	Lack of intrafollicular memory CD4 <sup>+</sup> T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer Journal, 2021, 11, 130.	6.2	27
69	O17-2 Tafasitamab + lenalidomide versus lenalidomide monotherapy in transplant-ineligible patients with R/R DLBCL (RE-MIND). Annals of Oncology, 2021, 32, S293.	1.2	0
70	Idelalisib immune-related toxicity is associated with improved treatment response. Leukemia and Lymphoma, 2021, 62, 1-6.	1.3	10
71	Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica, 2021, 106, 2417-2426.	3.5	81
72	Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial. Blood Cancer Journal, 2021, 11, 147.	6.2	10

#	ARTICLE	IF	CITATIONS
73	Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, , .	3.5	11
74	Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape. <i>Immunity</i> , 2021, 54, 1788-1806.e7.	14.3	43
75	RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6124-6134.	7.0	24
76	High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1324-1336.	3.7	15
77	Efficacy and safety of <sc>CD19</sc>-directed <sc>CAR</sc> cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the <sc>JULIET</sc>, <sc>ZUMA</sc>, and <sc>TRANSCEND</sc> trials. <i>American Journal of Hematology</i> , 2021, 96, 1295-1312.	4.1	107
78	Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?. <i>Blood Advances</i> , 2021, 5, 4185-4197.	5.2	15
79	ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S392-S393.	0.4	2
80	Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1403-1415.	10.7	222
81	Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3109-3117.	1.6	97
82	Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma. <i>European Journal of Cancer</i> , 2021, 157, 132-139.	2.8	4
83	Performances of Targeted RNA Sequencing for the Analysis of Fusion Transcripts, Gene Mutation, and Expression in Hematological Malignancies. <i>HemaSphere</i> , 2021, 5, e522.	2.7	2
84	Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study. <i>Cancer</i> , 2021, , .	4.1	1
85	Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. <i>Leukemia</i> , 2021, 35, 2108-2113.	7.2	13
86	Safety and Effectiveness of Idelalisib in Patients with Double-Refractory Follicular Lymphoma: A Pan-European Cohort of 242 Patients. <i>Blood</i> , 2021, 138, 1350-1350.	1.4	0
87	Molecular and Genetic Characterization of Tumor Samples from Patients with Relapsed or Refractory Follicular Lymphoma Identifies Factors Influencing Response to Tazemetostat. <i>Blood</i> , 2021, 138, 1183-1183.	1.4	1
88	Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2529-2529.	1.4	0
89	A Retrospective Cohort Study of Treatment Outcomes of Adult Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma (ReCORD-FL). <i>Blood</i> , 2021, 138, 1349-1349.	1.4	2
90	Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study. <i>Blood</i> , 2021, 138, 883-883.	1.4	7

#	ARTICLE	IF	CITATIONS
91	Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 183-183.	1.4	8
92	Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma. Blood, 2021, 138, 3528-3528.	1.4	3
93	Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL). Blood, 2021, 138, 2447-2447.	1.4	1
94	Addition of High-Dose Cytarabine to Immunochemotherapy before Autologous Stem-Cell Transplantation in Patients Aged 65 Years or Younger with Mantle Cell Lymphoma (MCL Younger): A Long-Term Follow-up of the Randomized, Open-Label, Phase 3 Trial of the European Mantle Cell Lymphoma Network. Blood, 2021, 138, 380-380.	1.4	10
95	Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance. Blood, 2021, 138, 2417-2417.	1.4	3
96	Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance. Blood, 2021, 138, 5031-5031.	1.4	0
97	Quantitative Change in Metabolic Tumor Volume May Assist in Distinguishing between Pseudoprogressors and Responders in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Treated with PD-1 Blockade. Blood, 2021, 138, 1402-1402.	1.4	0
98	Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). Blood, 2021, 138, 306-306.	1.4	5
99	Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas. Blood, 2021, 138, 809-809.	1.4	1
100	Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience. Blood, 2021, 138, 2513-2513.	1.4	0
101	Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience. Blood, 2021, 138, 4578-4578.	1.4	0
102	Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion. Blood, 2021, 138, 4098-4098.	1.4	0
103	TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma. Blood, 2021, 138, 710-710.	1.4	1
104	Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440). Haematologica, 2021, 106, 2834-2844.	3.5	3
105	Acute renal and splenic infarctions: a review. QJM - Monthly Journal of the Association of Physicians, 2020, 113, 186-193.	0.5	7
106	Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways. Human Molecular Genetics, 2020, 29, 70-79.	2.9	17
107	Reply to S. Fuji. Journal of Clinical Oncology, 2020, 38, 523-523.	1.6	1
108	Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Brutonâ€™s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). Leukemia, 2020, 34, 1458-1461.	7.2	15

#	ARTICLE	IF	CITATIONS
109	Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 248-256.	1.6	73
110	Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). <i>British Journal of Haematology</i> , 2020, 188, 240-248.	2.5	17
111	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1433-1442.	10.7	306
112	Early Off-Study Experience of Chimeric Antigen Receptor T Cells in Aggressive Lymphoma: Closer to a Real-World Setting. <i>Journal of Clinical Oncology</i> , 2020, 38, 3085-3087.	1.6	4
113	Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. <i>Blood Advances</i> , 2020, 4, 3217-3223.	5.2	16
114	How do I sequence therapy for follicular lymphoma?. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 287-294.	2.5	8
115	Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. <i>American Journal of Hematology</i> , 2020, 95, 1324-1333.	4.1	89
116	Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1079-1088.	4.1	16
117	Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. <i>Lancet Haematology</i> , the, 2020, 7, e649-e659.	4.6	24
118	ABCL-135: RE-MIND: A Comparison of Tafasitamab (MOR208) + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S265-S266.	0.4	2
119	ABCL-170: Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (MOR208) Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S267-S268.	0.4	3
120	Potential of Circulating Tumor DNA for the Management of Patients With Lymphoma. <i>JCO Oncology Practice</i> , 2020, 16, 561-568.	2.9	28
121	LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A REAL-LIFE™ STUDY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020020.	1.3	4
122	Drug cost savings in phase III hematological oncology clinical trials in a university hospital. <i>Hematological Oncology</i> , 2020, 38, 576-583.	1.7	3
123	International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. <i>Blood</i> , 2020, 135, 2041-2048.	1.4	158
124	Efficacy and Safety of Revaccination against Tetanus, Diphtheria, Haemophilus influenzae Type b and Hepatitis B Virus in a Prospective Cohort of Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1729-1737.	2.0	14
125	Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. <i>Blood</i> , 2020, 135, 996-1007.	1.4	49
126	Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 978-988.	10.7	320



#	ARTICLE	IF	CITATIONS
127	Gene expression profiling of gray zone lymphoma. <i>Blood Advances</i> , 2020, 4, 2523-2535.	5.2	32
128	Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. <i>Investigational New Drugs</i> , 2020, 38, 1472-1482.	2.6	8
129	Resources-Stratified Guidelines for Classical Hodgkin Lymphoma. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1783.	2.6	9
130	A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. <i>Clinical Cancer Research</i> , 2020, 26, 3145-3153.	7.0	48
131	Antibody Therapy Maintenance in Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 689-699.	2.2	2
132	Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases. <i>British Journal of Haematology</i> , 2020, 189, 244-256.	2.5	21
133	Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. <i>Leukemia</i> , 2020, 34, 2184-2197.	7.2	45
134	Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 510-520.	4.1	56
135	Impact of using leader primers for IGHV mutational status assessment in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 2257-2259.	7.2	4
136	Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. <i>Hematological Oncology</i> , 2020, 38, 137-145.	1.7	3
137	Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 629-637.	5.2	48
138	Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS). <i>Bone Marrow Transplantation</i> , 2020, 55, 2052-2055.	2.4	5
139	High total metabolic tumor volume at baseline predicts survival independent of response to therapy. <i>Blood</i> , 2020, 135, 1396-1405.	1.4	119
140	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. <i>Lancet</i> , 2020, 395, 1278-1291.	13.7	393
141	Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1074-1078.	2.5	13
142	On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 468-478.	4.1	29
143	Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. <i>Blood Advances</i> , 2020, 4, 560-572.	5.2	88
144	Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant. <i>Cancers</i> , 2020, 12, 901.	3.7	1

#	ARTICLE	IF	CITATIONS
145	Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma. Blood Cancer Journal, 2020, 10, 59.	6.2	22
146	Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205). Blood, 2020, 136, 43-44.	1.4	10
147	Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 2020, 136, 41-42.	1.4	2
148	Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5. Blood, 2020, 136, 34-34.	1.4	8
149	R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. Blood, 2020, 136, 39-40.	1.4	3
150	Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). Blood, 2020, 136, 40-41.	1.4	42
151	Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial. Blood, 2020, 136, 48-49.	1.4	25
152	Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension. Blood, 2020, 136, 17-19.	1.4	17
153	Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response. Blood, 2020, 136, 47-49.	1.4	3
154	PVAG Regimen (Prednisone, Vinblastine, Doxorubicin, Gemcitabine) Used in Real-Life Setting in First Line Therapy for Elderly Classical Hodgkin Lymphoma Patients: A Retrospective Study of Lysa Centers. Blood, 2020, 136, 11-11.	1.4	1
155	Diagnosis-to-Treatment Interval Is an Important Prognostic Factor with a Time-Dependent Effect Predicting Event-Free Survival after 12 Months from First-Line Treatment in Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma. Blood, 2020, 136, 43-45.	1.4	1
156	Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 46-47.	1.4	3
157	Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study. Blood, 2020, 136, 1-2.	1.4	1
158	Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 19-21.	1.4	9
159	Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).. Journal of Clinical Oncology, 2020, 38, 8008-8008.	1.6	42
160	RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2020, 38, 8020-8020.	1.6	11
161	Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARE and MEDication) Tj ETQq1 1 0.784314 rgBT /Over 2020, 15, e0243309.	2.5	2
162	The Biologic Interconnections Between Aging and Lymphoma. , 2020, , 141-152.		0

#	ARTICLE	IF	CITATIONS
163	Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study. <i>Blood</i> , 2020, 136, 42-43.	1.4	0
164	Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project. <i>Blood</i> , 2020, 136, 22-23.	1.4	2
165	Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study. <i>Blood</i> , 2020, 136, 34-35.	1.4	0
166	Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study. <i>Blood</i> , 2020, 136, 11-12.	1.4	6
167	NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry. <i>Blood</i> , 2020, 136, 20-21.	1.4	0
168	Safety Profile of Idelalisib in Patients with Refractory Follicular Lymphoma: Interim Analysis of a Noninterventional Study. <i>Blood</i> , 2020, 136, 48-50.	1.4	0
169	Estimation of Long-Term Survival with Tafasitamab + Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 9-10.	1.4	0
170	Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study. <i>Blood</i> , 2020, 136, 5-6.	1.4	0
171	Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy. <i>Blood</i> , 2020, 136, 22-23.	1.4	0
172	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. <i>Blood</i> , 2020, 136, 17-18.	1.4	0
173	Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. <i>Blood</i> , 2020, 136, 37-38.	1.4	1
174	Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study. <i>Blood</i> , 2020, 136, 25-26.	1.4	1
175	Retrospective Evaluation of Rituximab, Methotrexate, Procarbazine, Vincristine and Etoposide Followed By Consolidation with Rituximab, Aracytine and Ifosfamide for Elderly Patients with Newly Diagnosed Primary CNS Lymphoma. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
176	Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. <i>Genetic Epidemiology</i> , 2019, 43, 844-863.	1.3	28
177	Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1. <i>Oncology and Therapy</i> , 2019, 7, 121-130.	2.6	9
178	Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e470-e479.	4.6	20
179	Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. <i>Lancet Haematology</i> , 2019, 6, e429-e437.	4.6	64
180	Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2815-2824.	1.6	173

#	ARTICLE	IF	CITATIONS
181	Metagenomic Investigation of Torque Teno Mini Virus-SH in Hematological Patients. <i>Frontiers in Microbiology</i> , 2019, 10, 1898.	3.5	4
182	Unclassifiable Isolated Monoclonal Lymphocytosis: Comprehensive Description of a Retrospective Cohort. <i>Cancers</i> , 2019, 11, 1495.	3.7	0
183	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3291-3299.	1.6	195
184	Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux. <i>American Journal of Hematology</i> , 2019, 94, 1314-1324.	4.1	55
185	Prognostic Significance of <i>MYC</i> Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. <i>Journal of Clinical Oncology</i> , 2019, 37, 3359-3368.	1.6	161
186	Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S251-S252.	0.4	3
187	Early-onset severe infections in allogeneic hematopoietic stem cell transplantation recipients with graft failure. <i>American Journal of Hematology</i> , 2019, 94, E109-E111.	4.1	9
188	Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. <i>Leukemia and Lymphoma</i> , 2019, 60, 1610-1625.	1.3	16
189	Efficiency of blinatumomab in a t(8;21) acute myeloid leukemia expressing CD19. <i>Haematologica</i> , 2019, 104, e487-e488.	3.5	4
190	Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2676-2680.	3.0	4
191	New drugs for old targets. <i>Hematological Oncology</i> , 2019, 37, 101-104.	1.7	2
192	BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). <i>Annals of Hematology</i> , 2019, 98, 1973-1980.	1.8	2
193	Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b/2 study. <i>Lancet Oncology</i> , The, 2019, 20, 998-1010.	10.7	101
194	Human herpesvirus 6 infection after autologous stem cell transplantation: A multicenter prospective study in adult patients. <i>Journal of Infection</i> , 2019, 79, 36-42.	3.3	11
195	Unravelling Subtleties of Angioimmunoblastic T-Cell Lymphoma. <i>Journal of Oncology Practice</i> , 2019, 15, 147-148.	2.5	0
196	Prolonged Improvement in Patient Reported Quality of Life (QoL) Following Tisagenlecleucel Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL): 19-Month Follow-up (FU) of the Juliet Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S181-S182.	2.0	4
197	Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience. <i>Cancers</i> , 2019, 11, 570.	3.7	14
198	Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study. <i>Cancer</i> , 2019, 125, 2291-2299.	4.1	14

#	ARTICLE	IF	CITATIONS
199	VaccHemInf project: protocol for a prospective cohort study of efficacy, safety and characterisation of immune functional response to vaccinations in haematopoietic stem cell transplant recipients. <i>BMJ Open</i> , 2019, 9, e026093.	1.9	8
200	Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. <i>Blood</i> , 2019, 133, 1964-1976.	1.4	104
201	Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 144-152.	1.6	142
202	Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). <i>Lancet Haematology</i> , 2019, 6, e254-e265.	4.6	184
203	Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S20-S21.	2.0	28
204	Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 275-284.	0.4	30
205	Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 341-351.	3.7	61
206	POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R-CHP VERSUS R-CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL. <i>Hematological Oncology</i> , 2019, 37, 68-70.	1.7	4
207	Pattern of Care and Outcomes of Adolescent and Young Adults with Lymphoma Treated in the Rhône-Alpes Region. <i>Journal of Adolescent and Young Adult Oncology</i> , 2019, 8, 684-696.	1.3	1
208	Single-agent ibrutinib in RESONATE-2 and RESONATE versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2019, 98, 2749-2760.	1.8	9
209	The Need for a Consensus Next-Generation Sequencing Panel for Mature Lymphoid Malignancies. <i>HemaSphere</i> , 2019, 3, e169.	2.7	26
210	Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles. <i>EBioMedicine</i> , 2019, 48, 58-69.	6.1	29
211	Impact of NPM1 mutation subtypes on treatment outcome in AML: The Lyon-University Hospital experience. <i>Leukemia Research</i> , 2019, 76, 29-32.	0.8	2
212	Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2019, 380, 45-56.	27.0	2,594
213	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet</i> , 2019, 393, 229-240.	13.7	517
214	Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study. <i>Leukemia</i> , 2019, 33, 776-780.	7.2	16
215	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 1539.	2.8	6
216	Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia. <i>Blood</i> , 2019, 134, 4006-4006.	1.4	5

#	ARTICLE	IF	CITATIONS
217	Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 1582-1582.	1.4	1
218	Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gdolin Study. <i>Blood</i> , 2019, 134, 2822-2822.	1.4	3
219	Sub-Cutaneous Rituximab-Minichop Versus Sub-Cutaneous Rituximab-Minichop + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More (SENIOR Study). a Multicentric Randomized Phase III Study of the Lysa. <i>Blood</i> , 2019, 134, 352-352.	1.4	7
220	Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial. <i>Blood</i> , 2019, 134, 1584-1584.	1.4	24
221	Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC). <i>Blood</i> , 2019, 134, 400-400.	1.4	2
222	Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel. <i>Blood</i> , 2019, 134, 2883-2883.	1.4	15
223	A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 5310-5310.	1.4	3
224	Mutational Landscape of Grey Zone Lymphoma. <i>Blood</i> , 2019, 134, 21-21.	1.4	3
225	A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial. <i>Blood</i> , 2019, 134, 2877-2877.	1.4	3
226	Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , 2019, 134, 123-123.	1.4	33
227	Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL). <i>Blood</i> , 2019, 134, 242-242.	1.4	8
228	ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 31-31.	1.4	47
229	Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 4079-4079.	1.4	21
230	Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial. <i>Blood</i> , 2019, 134, 1524-1524.	1.4	3
231	Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. <i>Blood</i> , 2019, 134, 4103-4103.	1.4	24
232	A French Multicentric Prospective Cohort of 6000 Patients with Integrative Epidemiological, Clinical, Biological and Treatment Data to Improve Knowledge on Outcome of Lymphoma Patients: Pilot Phase Results of the Real World Data in Lymphoma and Survival in Adults (REALYSA) Study. <i>Blood</i> , 2019, 134, 4762-4762.	1.4	1
233	Correction to: Aggressive Lymphomas. <i>Technik Im Fokus</i> , 2019, , C1-C1.	0.2	0
234	Aggressive Lymphomas. <i>Hematologic Malignancies</i> , 2019, , .	0.2	1

#	ARTICLE	IF	CITATIONS
235	Individualized Prediction of Follicular Lymphoma Risk Using a Combination of Blood t(14;18) Frequency Years before Diagnosis and a Polygenic Risk Score (PRS) of 9 SNPs Associated with Follicular Lymphoma Susceptibility. <i>Blood</i> , 2019, 134, 2775-2775.	1.4	0
236	A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group. <i>Blood</i> , 2019, 134, 2812-2812.	1.4	0
237	Combining Gene Expression Profiling and Artificial Intelligence to Diagnose B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1476-1476.	1.4	1
238	Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial. <i>Blood</i> , 2019, 134, 3038-3038.	1.4	0
239	Implication of Inherited Genetic Variants Associated with Follicular Lymphoma Susceptibility in the Prognosis of Patients Treated By Immunochemotherapy in PRIMA Study. <i>Blood</i> , 2019, 134, 2780-2780.	1.4	0
240	Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study). <i>Blood</i> , 2019, 134, 2765-2765.	1.4	0
241	Follicular lymphoma: twenty years of progress, and multiple challenges. <i>Hematologie</i> , 2019, 25, 2-2.	0.0	0
242	A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. <i>Lancet Oncology</i> , The, 2018, 19, 549-561.	10.7	165
243	Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1001-1009.	2.4	23
244	Case report. <i>Medicine (United States)</i> , 2018, 97, e9657.	1.0	7
245	Management of relapsed or refractory follicular lymphoma patients in daily practice â€“ a French non-interventional study. <i>Leukemia and Lymphoma</i> , 2018, 59, 2485-2488.	1.3	2
246	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018, 132, 49-58.	1.4	130
247	Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries. <i>Leukemia and Lymphoma</i> , 2018, 59, 2113-2120.	1.3	6
248	From genetics to the clinic: a translational perspective on follicular lymphoma. <i>Nature Reviews Cancer</i> , 2018, 18, 224-239.	28.4	108
249	Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. <i>Annals of Oncology</i> , 2018, 29, 715-723.	1.2	110
250	Refractory diffuse large Bâ€“cell lymphoma after firstâ€“line immunoâ€“CT: Treatment options and outcomes. <i>Hematological Oncology</i> , 2018, 36, 533-542.	1.7	5
251	Authorsâ€™ Reply. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 266.	2.8	0
252	Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. <i>Blood</i> , 2018, 131, 2449-2453.	1.4	49

#	ARTICLE	IF	CITATIONS
253	Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e211-e218.	0.4	5
254	A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <i>MYC</i> predicts patient outcome in two independent cohorts. <i>British Journal of Haematology</i> , 2018, 180, 286-290.	2.5	13
255	Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the <i>FLO</i> group. <i>American Journal of Hematology</i> , 2018, 93, E24-E27.	4.1	2
256	Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?. <i>Hematological Oncology</i> , 2018, 36, 399-406.	1.7	25
257	SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma. <i>Annals of Hematology</i> , 2018, 97, 123-131.	1.8	12
258	Tumor-infiltrating T lymphocytes and morphogenesis of follicular lymphoma—reply. <i>Human Pathology</i> , 2018, 72, 198-199.	2.0	0
259	A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D2; Tj ETQq1 1 0.784314 rgBT /Overlock	1.8	110
260	Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2259-2266.	1.6	107
261	Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2405-2412.	1.6	81
262	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	1.6	93
263	Through the Glass Ceiling. <i>Journal of Clinical Oncology</i> , 2018, 36, 923-923.	1.6	0
264	Definition of a minimal genes set for mature lymphoid blood diseases. <i>Hematologie</i> , 2018, 24, 27-59.	0.0	4
265	PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors. <i>Annals of Oncology</i> , 2018, 29, viii20.	1.2	4
266	New Treatment Options in Advanced Stage Follicular Lymphoma. <i>HemaSphere</i> , 2018, 2, e156.	2.7	1
267	Metagenomic Next-Generation Sequencing Reveals Individual Composition and Dynamics of Anelloviruses during Autologous Stem Cell Transplant Recipient Management. <i>Viruses</i> , 2018, 10, 633.	3.3	23
268	Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S278-S279.	0.4	5
269	Chronic <i>Borrelia burgdorferi</i> infection triggers NKT lymphomagenesis. <i>Blood</i> , 2018, 132, 2691-2695.	1.4	4
270	Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2018, 379, 934-947.	27.0	264



#	ARTICLE	IF	CITATIONS
271	Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. <i>Lancet Haematology</i> , 2018, 5, e403-e410.	4.6	21
272	Successful pregnancies in patients with BCR-ABL-positive leukemias treated with interferon- $\alpha$ therapy during the tyrosine kinase inhibitors era. <i>European Journal of Haematology</i> , 2018, 101, 774-780.	2.2	17
273	Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. <i>Lancet Haematology</i> , 2018, 5, e359-e367.	4.6	74
274	An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. <i>Blood</i> , 2018, 132, 1486-1494.	1.4	25
275	One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 704.	4.8	15
276	What Does This Mutation Mean? The Tools and Pitfalls of Variant Interpretation in Lymphoid Malignancies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1251.	4.1	11
277	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. <i>Cancer Research</i> , 2018, 78, 4086-4096.	0.9	34
278	Human germinal center transcriptional programs are de-synchronized in B cell lymphoma. <i>Nature Immunology</i> , 2018, 19, 1013-1024.	14.5	115
279	Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life. <i>Blood</i> , 2018, 132, 865-867.	1.4	18
280	Predictive gene-expression score for follicular lymphoma – Authors' reply. <i>Lancet Oncology</i> , The, 2018, 19, e282.	10.7	2
281	FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e545-e550.	0.4	19
282	Abstract CT110: Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). <i>Cancer Research</i> , 2018, 78, CT110-CT110.	0.9	2
283	CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial. <i>Blood</i> , 2018, 132, 226-226.	1.4	24
284	Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 449-449.	1.4	4
285	Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. <i>Blood</i> , 2018, 132, 228-228.	1.4	14
286	Non-Interventional Retrospective Multicenter Study Evaluating Real World Idelalisib Use in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma Patients Enrolled in the French Early Access Program. <i>Blood</i> , 2018, 132, 5924-5924.	1.4	1
287	Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 4189-4189.	1.4	4
288	A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untreated Follicular B-Cell Lymphoma in Need of Systemic Therapy. <i>Blood</i> , 2018, 132, 446-446.	1.4	2

#	ARTICLE	IF	CITATIONS
289	The Burden of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Systematic Literature Review (SLR). <i>Blood</i> , 2018, 132, 2241-2241.	1.4	4
290	Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study. <i>Blood</i> , 2018, 132, 4191-4191.	1.4	3
291	Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind. <i>Blood</i> , 2018, 132, 227-227.	1.4	4
292	Atezolizumab in Combination with Obinutuzumab and Lenalidomide Demonstrates Favorable Activity and Manageable Toxicity in Patients with Relapsed/Refractory Follicular Lymphoma (FL): An Interim Analysis of a Phase Ib/II Trial. <i>Blood</i> , 2018, 132, 1603-1603.	1.4	4
293	Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. <i>Blood</i> , 2018, 132, 4097-4097.	1.4	5
294	Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel. <i>Blood</i> , 2018, 132, 1684-1684.	1.4	28
295	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , 2018, 132, 922-922.	1.4	2
296	Desynchronization of the Germinal Center Dynamics and Remodeling of the Tumor Microenvironment Characterize KMT2D-Driven Lymphomagenesis. <i>Blood</i> , 2018, 132, 670-670.	1.4	8
297	Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440). <i>Blood</i> , 2018, 132, 1859-1859.	1.4	1
298	Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study. <i>Blood</i> , 2018, 132, 782-782.	1.4	27
299	RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R <sup>2</sup> ) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7500-7500.	1.6	9
300	Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Final analysis of the AHL2011 LYSA study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7503-7503.	1.6	12
301	Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7507-7507.	1.6	45
302	A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7589-TPS7589.	1.6	3
303	Toll-like receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma. <i>Oncotarget</i> , 2018, 9, 23589-23598.	1.8	4
304	The Biologic Interconnections Between Aging and Lymphoma. , 2018, , 1-12.		0
305	A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS2603-TPS2603.	1.6	1
306	Ibrutinib in association with R-DHAP/ox for patients with relapsed/refractory b-cell lymphoma: Results of the escalating phase of the BIBLOS phase Ib LYSA study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e19550-e19550.	1.6	1

#	ARTICLE	IF	CITATIONS
307	Abstract 4921: Population pharmacokinetic modeling of ibrutinib administered in patients with relapsed or refractory B cell malignancies eligible for autologous stem cell transplantation. , 2018, , .		0
308	Abstract 221: Inherited variants at 3q13.33 and 3p24.1 influences risk of diffuse large B-cell lymphoma. , 2018, , .		0
309	High Rate of Complete Response (CR) with Undetectable Bone Marrow Minimal Residual Disease (MRD) after Chemo-Sparing and MRD-Driven Strategy for Untreated Fit CLL Patients: Final Results of the Icll 07 Filo Trial. Blood, 2018, 132, 1858-1858.	1.4	0
310	A New Simplified Prognostic Index Integrating the Type of Extra-Nodal Involvement and Age for Ann Arbor Stage IV Hodgkin Lymphoma Patients Diagnosed at TEP-Scanner Era: A Retrospective Analysis from Lymphoma Study Association (LYSA) Centers. Blood, 2018, 132, 1629-1629.	1.4	0
311	Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma. Blood, 2018, 132, 5345-5345.	1.4	0
312	Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma. Blood, 2018, 132, 4145-4145.	1.4	0
313	Identification of a Genetic Signature Enriching for Response to Ibrutinib in Relapsed/Refractory Follicular Lymphoma in the Dawn Phase 2 Trial. Blood, 2018, 132, 4147-4147.	1.4	0
314	Single-Agent Ibrutinib vs Real-World (RW) Treatments for Patients with Chronic Lymphocytic Leukemia (CLL) and del11q: Adjusted Comparison of RESONATE-2TM and RESONATE2TM with RW Databases. Blood, 2018, 132, 4427-4427.	1.4	1
315	Follicular Lymphoma Grade 3A Exhibits Pathological and Cytogenetic Diversity, but Similar Prognosis Compared to FL Grade 1-2: Pooled Analysis of 1757 Follicular Lymphomas from the PRIMA and Relevance Trials. Blood, 2018, 132, 778-778.	1.4	0
316	Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study. Blood, 2018, 132, 4199-4199.	1.4	0
317	Efficacy of Ibrutinib-Rituximab versus Real-World (RW) Treatments for Patients with Waldenström's Macroglobulinemia (WM): Adjusted Comparison of iNNOVATE and the Lyon-Sud RW Database. Blood, 2018, 132, 1604-1604.	1.4	5
318	Ritumixab in Combination with Adapted-Dose of Ifosfamide and Etoposide As Salvage Treatment in Elderly Refractory/Relapsed Diffuse Large B-Cell Lymphoma Patients Non-Candidate for High Dose Therapy: A Retrospective Study of Lyon Hospital University. Blood, 2018, 132, 4215-4215.	1.4	0
319	Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma. Blood, 2018, 132, 5344-5344.	1.4	0
320	Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70) Tj ETQq0 0 Q rrgBT /Overlock 10 T	1.3	12
321	Primary cardiac lymphoma: diagnosis, treatment and outcome in a modern series. Hematological Oncology, 2017, 35, 510-519.	1.7	46
322	<i>FCGR3A</i>/<i>2A</i> polymorphisms and diffuse large Bâ€cell lymphoma outcome treated with immunochemotherapy: a metaâ€analysis on 1134 patients from two prospective cohorts. Hematological Oncology, 2017, 35, 447-455.	1.7	9
323	Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. Journal of Clinical Oncology, 2017, 35, 536-543.	1.6	168
324	Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review. Bone Marrow Transplantation, 2017, 52, 941-949.	2.4	22

#	ARTICLE	IF	CITATIONS
325	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 552-560.	1.6	87
326	BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab. <i>American Journal of Hematology</i> , 2017, 92, 515-519.	4.1	22
327	Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. <i>Haematologica</i> , 2017, 102, 150-159.	3.5	61
328	Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101. <i>Leukemia Research</i> , 2017, 55, 41-48.	0.8	5
329	Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. <i>Blood</i> , 2017, 129, 2616-2623.	1.4	73
330	EZH2 alterations in follicular lymphoma: biological and clinical correlations. <i>Blood Cancer Journal</i> , 2017, 7, e555-e555.	6.2	70
331	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2017, 102, 1413-1423.	3.5	39
332	Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients. <i>Human Pathology</i> , 2017, 64, 128-136.	2.0	25
333	Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 623-632.	3.1	2
334	Cat-Scratch Disease. <i>Clinical Nuclear Medicine</i> , 2017, 42, 106-107.	1.3	5
335	Usual and unusual pitfalls of 18F-FDG-PET/CT in lymphoma after treatment. <i>Nuclear Medicine Communications</i> , 2017, 38, 563-576.	1.1	15
336	ABVD or BEACOPP baseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC) "Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. <i>European Journal of Cancer</i> , 2017, 81, 45-55.	2.8	33
337	BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. <i>Annals of Oncology</i> , 2017, 28, 1042-1049.	1.2	21
338	Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. <i>Blood</i> , 2017, 129, 2808-2810.	1.4	48
339	Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. <i>Blood</i> , 2017, 129, 3037-3039.	1.4	68
340	Rituximab maintenance improves overall survival of patients with follicular lymphoma "Individual patient data meta-analysis. <i>European Journal of Cancer</i> , 2017, 76, 216-225.	2.8	50
341	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i> , 2017, 28, 1436-1447.	1.2	249
342	A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4127-4137.	7.0	135

#	ARTICLE	IF	CITATIONS
343	Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area. <i>Blood</i> , 2017, 129, 2811-2813.	1.4	2
344	Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?. <i>Annals of Hematology</i> , 2017, 96, 363-371.	1.8	9
345	Ibrutinib-Induced Lymphocytosis: Cytological Features. <i>Acta Haematologica</i> , 2017, 137, 55-57.	1.4	4
346	Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. <i>Clinical Cancer Research</i> , 2017, 23, 2232-2244.	7.0	82
347	Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. <i>Haematologica</i> , 2017, 102, e156-e159.	3.5	68
348	Comprehensive analysis of a myeloperoxidase-negative acute promyelocytic leukemia. <i>Blood</i> , 2017, 129, 128-131.	1.4	5
349	Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S380-S381.	0.4	3
350	Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. <i>Advances in Therapy</i> , 2017, 34, 2232-2273.	2.9	407
351	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 1250-1260.	27.0	313
352	Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 892-904.	2.8	39
353	Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) – An Interim Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S373-S374.	0.4	13
354	L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) - A SINGLE-ARM PHASE II STUDY. <i>Hematological Oncology</i> , 2017, 35, 51-52.	1.7	1
355	POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA. <i>Hematological Oncology</i> , 2017, 35, 90-91.	1.7	11
356	Isolated hepatosplenic sarcoidosis: A pitfall for lymphoma evaluation by 18 F-FDG PET/CT. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2017, 36, 399-400.	0.0	0
357	Exome sequencing identifies recurrent <i>BCOR</i> alterations and the absence of <i>KLF2</i> , <i>TNFAIP3</i> and <i>MYD88</i> mutations in splenic diffuse red pulp small B-cell lymphoma. <i>Haematologica</i> , 2017, 102, 1758-1766.	3.5	54
358	Research protocol on early palliative care in patients with acute leukaemia after one relapse. <i>BMJ Supportive and Palliative Care</i> , 2017, 7, 480-484.	1.6	5
359	[OP.4B.09] IMPORTANCE OF CLINIC AND AMBULATORY BLOOD PRESSURES AS PREDICTORS OF DEVELOPMENT AND PROGRESSION OF DIABETIC KIDNEY DISEASE. <i>Journal of Hypertension</i> , 2017, 35, e40.	0.5	0
360	Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. <i>Anti-Cancer Drugs</i> , 2017, 28, 341-349.	1.4	10

#	ARTICLE	IF	CITATIONS
361	Diffuse Subcutaneous Fat Involvement in a Marginal Zone Lymphoma. <i>Clinical Nuclear Medicine</i> , 2017, 42, 129-130.	1.3	4
362	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	2.7	15
363	Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Haematologica</i> , 2017, 102, 2104-2112.	3.5	41
364	Absence of driver mutations in persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes. <i>Blood</i> , 2017, 130, 1267-1269.	1.4	10
365	Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay. <i>Haematologica</i> , 2017, 102, e404-e406.	3.5	16
366	Bone Marrow Necrosis in Newly Diagnosed Acute Leukemia: Two Case Reports and Review of the Literature. <i>Oncology and Therapy</i> , 2017, 5, 111-118.	2.6	8
367	Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study. <i>Hematological Oncology</i> , 2017, 35, 210-211.	1.7	0
368	Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 221-230.	2.8	10
369	Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients. <i>Hematological Oncology</i> , 2017, 35, 584-590.	1.7	28
370	Acute myeloid leukemia in the elderly (age 70 yr or older): long-term survivors. <i>European Journal of Haematology</i> , 2017, 98, 134-141.	2.2	9
371	Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2017, 58, 666-675.	1.3	18
372	Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. <i>Blood Advances</i> , 2017, 1, 1884-1890.	5.2	40
373	High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia. <i>World Journal of Stem Cells</i> , 2017, 9, 227-234.	2.8	31
374	Report: LYSA 2016. <i>Hematologie</i> , 2017, 23, 4-4.	0.0	0
375	Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. <i>Journal of Clinical Oncology</i> , 2017, 35, 2008-2017.	1.6	155
376	Reply to H.J.A. Adams et al and E. Laffon et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 920-923.	1.6	3
377	Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2017, 35, 2473-2481.	1.6	148
378	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1905-1912.	1.6	143

#	ARTICLE	IF	CITATIONS
379	L-mind: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL)â€”A single-arm phase II study.. Journal of Clinical Oncology, 2017, 35, 7514-7514.	1.6	1
380	Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2017, 35, 7536-7536.	1.6	6
381	Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).. Journal of Clinical Oncology, 2017, 35, TPS7575-TPS7575.	1.6	3
382	The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. Oncotarget, 2017, 8, 8765-8774.	1.8	69
383	Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT. Oncotarget, 2017, 8, 85110-85119.	1.8	2
384	Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b/ICAM-1 binding. Oncotarget, 2017, 8, 72818-72834.	1.8	14
385	Preliminary results of a phase Ib study of GS-4059 in combination with entospletinib in patients with B-cell malignancies.. Journal of Clinical Oncology, 2017, 35, 7518-7518.	1.6	0
386	CheckMate 436: A phase 1-2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas.. Journal of Clinical Oncology, 2017, 35, TPS7577-TPS7577.	1.6	0
387	TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016009.	1.3	17
388	Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma: Randomized phase 3 KEYNOTE-204 study. Annals of Oncology, 2016, 27, viii17.	1.2	0
389	Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large <sc>B</sc>â€œcell lymphoma. Genes Chromosomes and Cancer, 2016, 55, 251-267.	2.8	75
390	FDG PET/CT Findings in Abdominal Fat Necrosis After Treatment for Lymphoma. Clinical Nuclear Medicine, 2016, 41, 397-398.	1.3	4
391	Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal Bâ€œcell lymphoma. American Journal of Hematology, 2016, 91, 923-930.	4.1	79
392	Personalized risk prediction for eventâ€œfree survival at 24 months in patients with diffuse large Bâ€œcell lymphoma. American Journal of Hematology, 2016, 91, 179-184.	4.1	41
393	Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. Journal of Clinical Oncology, 2016, 34, 2575-2582.	1.6	142
394	Idelalisib. Cancer Journal (Sudbury, Mass ), 2016, 22, 12-16.	2.0	4
395	Rapamycin safeguards lymphocytes from DNA damage accumulation in vivo. European Journal of Cell Biology, 2016, 95, 331-341.	3.6	9
396	<sc>CD</sc>180 overexpression in follicular lymphoma is restricted to the lymph node compartment. Cytometry Part B - Clinical Cytometry, 2016, 90, 433-439.	1.5	10

#	ARTICLE	IF	CITATIONS
397	<sc>S</sc>tatin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: <sc>A</sc>n exploratory analysis of the PRIMA cohort study. American Journal of Hematology, 2016, 91, 410-415.	4.1	5
398	Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. OncoImmunology, 2016, 5, e1186323.	4.6	2
399	Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (cHL): randomized phase 3 KEYNOTE-204 study. Annals of Oncology, 2016, 27, vi327.	1.2	1
400	Targeting netrinâ€1/<sc>DCC</sc> interaction in diffuse large Bâ€cell and mantle cell lymphomas. EMBO Molecular Medicine, 2016, 8, 96-104.	6.9	19
401	A matched caseâ€control study of toxoplasmosis after allogeneic haematopoieticâ€stem cell transplantation: still a devastating complication. Clinical Microbiology and Infection, 2016, 22, 636-641.	6.0	35
402	Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet, The, 2016, 387, 2402-2411.	13.7	157
403	CD1d-restricted peripheral T cell lymphoma in mice and humans. Journal of Experimental Medicine, 2016, 213, 841-857.	8.5	19
404	Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Haematologica, 2016, 101, 474-481.	3.5	44
405	Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies. Leukemia and Lymphoma, 2016, 57, 2820-2826.	1.3	13
406	A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood, 2016, 127, 411-419.	1.4	231
407	The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 2016, 127, 2375-2390.	1.4	5,965
408	Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. Blood, 2016, 128, 1625-1630.	1.4	78
409	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. American Journal of Hematology, 2016, 91, 1096-1101.	4.1	180
410	Baseline Metabolic Tumor Volume Predicts Outcome in Highâ€Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. Journal of Clinical Oncology, 2016, 34, 3618-3626.	1.6	231
411	Molecular Classification of Diffuse Large B-cell Lymphoma. Hematology/Oncology Clinics of North America, 2016, 30, 1163-1177.	2.2	22
412	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, v83-v90.	1.2	166
413	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet, The, 2016, 388, 565-575.	13.7	328
414	An 18F-FDG-PET maximum standardized uptake valueâ€%>â€10 represents a novel valid marker for discerning Richterâ€s Syndrome. Leukemia and Lymphoma, 2016, 57, 1474-1477.	1.3	47



#	ARTICLE	IF	CITATIONS
415	Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1081-1093.	10.7	297
416	The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2016, 47, 1-7.	0.8	9
417	Actinomycosis after allogeneic hematopoietic stem cell transplantation despite penicillin prophylaxis. <i>Transplant Infectious Disease</i> , 2016, 18, 595-600.	1.7	6
418	A high rate of telomeric sister chromatid exchange occurs in chronic lymphocytic leukaemia B cells. <i>British Journal of Haematology</i> , 2016, 174, 57-70.	2.5	18
419	Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study. <i>Clinical Cancer Research</i> , 2016, 22, 2919-2928.	7.0	181
420	Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 572-580.	1.6	76
421	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. <i>Lancet Oncology</i> , The, 2016, 17, 200-211.	10.7	373
422	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. <i>Human Molecular Genetics</i> , 2016, 25, 1663-1676.	2.9	52
423	Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. <i>Haematologica</i> , 2016, 101, 226-234.	3.5	31
424	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. <i>Lancet Haematology</i> , the, 2016, 3, e196-e204.	4.6	344
425	Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2016, 27, 390-397.	1.2	54
426	Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA. <i>Annals of Oncology</i> , 2016, 27, 1349-1350.	1.2	13
427	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , 2016, 101, 115-208.	3.5	67
428	Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 723-730.	2.0	61
429	Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. <i>Bone Marrow Transplantation</i> , 2016, 51, 212-218.	2.4	45
430	Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials. <i>Leukemia</i> , 2016, 30, 1428-1430.	7.2	19
431	Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. <i>Bone Marrow Transplantation</i> , 2016, 51, 51-57.	2.4	216
432	Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 852-865.	1.3	4

#	ARTICLE	IF	CITATIONS
433	Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study. <i>Blood</i> , 2016, 128, 1102-1102.	1.4	3
434	Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study. <i>Blood</i> , 2016, 128, 1217-1217.	1.4	9
435	Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group. <i>Blood</i> , 2016, 128, 145-145.	1.4	38
436	Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study. <i>Blood</i> , 2016, 128, 1853-1853.	1.4	5
437	Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies. <i>Blood</i> , 2016, 128, 2961-2961.	1.4	1
438	Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study. <i>Blood</i> , 2016, 128, 2980-2980.	1.4	3
439	Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 3032-3032.	1.4	12
440	Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 3233-3233.	1.4	2
441	A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials. <i>Blood</i> , 2016, 128, 3705-3705.	1.4	23
442	A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4202-4202.	1.4	4
443	Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4393-4393.	1.4	17
444	First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa. <i>Blood</i> , 2016, 128, 471-471.	1.4	12
445	Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): High Efficacy of High Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC auto-SCT). A Study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 514-514.	1.4	1
446	Ibrutinib in Association with R-DHAP/Ox for Patients with Relapsed/Refractory B-Cell Lymphoma: Preliminary Results of the Biblos Phase Ib Lysa Study. <i>Blood</i> , 2016, 128, 5384-5384.	1.4	3
447	Temporal Profiles of Lymphocyte Subsets and the Correlation with Infectious Events in Idelalisib-Treated Patients. <i>Blood</i> , 2016, 128, 5583-5583.	1.4	3
448	Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study. <i>Blood</i> , 2016, 128, 615-615.	1.4	22
449	Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7509-7509.	1.6	15
450	Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7518-7518.	1.6	1

#	ARTICLE	IF	CITATIONS
451	Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma.. Journal of Clinical Oncology, 2016, 34, 7566-7566.	1.6	5
452	A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs).. Journal of Clinical Oncology, 2016, 34, TPS7576-TPS7576.	1.6	1
453	Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2016, 34, TPS7582-TPS7582.	1.6	12
454	Management of transaminase elevations in patients receiving idelalisib.. Journal of Clinical Oncology, 2016, 34, 7532-7532.	1.6	0
455	Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system.. Journal of Clinical Oncology, 2016, 34, 7547-7547.	1.6	0
456	Allogeneic anti-CD19 CAR T cells: new perspectives in the treatment of B-cell malignancies that progress after allogeneic stem cell transplantation?. Translational Cancer Research, 2016, 5, S5-S8.	1.0	0
457	Mutation Load and a Functional T Effector Signature May Distinguish Immunologically Distinct and Clinically Relevant Lymphoma Subsets. Blood, 2016, 128, 913-913.	1.4	1
458	Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and Non-L265P Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. Blood, 2016, 128, 4097-4097.	1.4	0
459	Integrated Analysis of IGHV Gene Status, Cell-of-Origin Signature and Genomic Features in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 4118-4118.	1.4	0
460	Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa Studies. Blood, 2016, 128, 927-927.	1.4	0
461	Fractionated Gemtuzumab Ozogamicin Combined with Intermediate-Dose Cytarabine and Daunorubicin As Salvage Therapy in Very High Risk AML Patients: A Bridge to Reduced Intensity Conditioning Transplant?. Blood, 2016, 128, 4003-4003.	1.4	0
462	Outcome Analysis of High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma: A Francophone Society of Bone Marrow Transplantation and Cellular Therapy Study. Blood, 2016, 128, 3458-3458.	1.4	0
463	Genome-Wide Association Study of the Human Genetic Factors Influencing the Risk of Adverse Events during Idelalisib Therapy in Patients with Relapsed Indolent Lymphoma. Blood, 2016, 128, 5284-5284.	1.4	0
464	Evaluation of Immune Mechanisms to Understand Idelalisib-Associated Diarrhea-Colitis. Blood, 2016, 128, 5588-5588.	1.4	0
465	Early Human Herpes Virus 6 Infection after Autologous Stem Cell Transplantation: A Multicenter Prospective Observational Study of 196 Patients (VIRAUTO 6). Blood, 2016, 128, 3698-3698.	1.4	0
466	Single-Agent Ibrutinib Vs Standard of Care for Patients with Relapsed/Refractory (R/R) and Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): An Adjusted Comparison of RESONATE™ and RESONATE-2™ with the French Lyon-Sud Database. Blood, 2016, 128, 2039-2039.	1.4	0
467	MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood, 2015, 126, 2466-2474.	1.4	212
468	Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood, 2015, 126, 2646-2649.	1.4	64

#	ARTICLE	IF	CITATIONS
469	Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma. <i>Haematologica</i> , 2015, 100, e269-e271.	3.5	24
470	PP.26.13. <i>Journal of Hypertension</i> , 2015, 33, e361.	0.5	0
471	Lenalidomide is safe and active in <scp>W</scp>aldenstrÅm macroglobulinemia. <i>American Journal of Hematology</i> , 2015, 90, 1055-1059.	4.1	23
472	PP.19.06. <i>Journal of Hypertension</i> , 2015, 33, e299.	0.5	0
473	International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20-Positive B Cell PTLD: Clues From the PTLD-1 Trial. <i>American Journal of Transplantation</i> , 2015, 15, 1091-1100.	4.7	48
474	High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. <i>Blood</i> , 2015, 126, 604-611.	1.4	130
475	The Biology of Aging and Lymphoma: a Complex Interplay. <i>Current Oncology Reports</i> , 2015, 17, 32.	4.0	26
476	Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma. <i>Haematologica</i> , 2015, 100, e204-e206.	3.5	14
477	Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era. <i>Leukemia and Lymphoma</i> , 2015, 56, 1959-1968.	1.3	26
478	Chemotherapy-free treatment in patients with follicular lymphoma. <i>Expert Review of Hematology</i> , 2015, 8, 187-203.	2.2	8
479	Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines. <i>Scientific Reports</i> , 2015, 5, 8068.	3.3	23
480	The p16INK4A/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome. <i>Leukemia Research</i> , 2015, 39, 453-461.	0.8	8
481	CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. <i>Haematologica</i> , 2015, 100, 1086-95.	3.5	37
482	Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 704-715.	10.7	272
483	Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Like Multiplex Ligation-Dependent Probe Amplification Assay. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 273-283.	2.8	50
484	Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. <i>Journal of Clinical Oncology</i> , 2015, 33, 1482-1490.	1.6	60
485	Biosimilar monoclonal antibodies in lymphoma: a critical appraisal. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 569-578.	2.4	12
486	Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. <i>Leukemia</i> , 2015, 29, 1578-1586.	7.2	131

#	ARTICLE	IF	CITATIONS
487	Treatment Approach to Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Seminars in Hematology</i> , 2015, 52, 107-118.	3.4	16
488	The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association. <i>Clinical Cancer Research</i> , 2015, 21, 3428-3435.	7.0	101
489	Effect of Initial Body Mass Index on Survival Outcome of Patients With Acute Leukemia: A Single-Center Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S7-S13.	0.4	8
490	Transfusion dependency at diagnosis and transfusion intensity during initial chemotherapy are associated with poorer outcomes in adult acute myeloid leukemia. <i>Annals of Hematology</i> , 2015, 94, 1797-1806.	1.8	13
491	EPICC study: evaluation of pharmaceutical intervention in cancer care. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 196-203.	1.5	26
492	Obinutuzumab in hematologic malignancies: Lessons learned to date. <i>Cancer Treatment Reviews</i> , 2015, 41, 784-792.	7.7	52
493	Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the Lymphoma Study Association (LYSA). <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 939-948.	2.3	7
494	Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 3930-3937.	1.6	24
495	Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study. <i>Blood</i> , 2015, 126, 129-129.	1.4	2
496	An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2015, 126, 1493-1493.	1.4	5
497	Quantitative Assessment of Circulating Clonal IG-VDJ Sequences in Plasma of Follicular Lymphoma at Diagnosis Is Highly Predictive of Progression Free Survival (PFS). <i>Blood</i> , 2015, 126, 2675-2675.	1.4	4
498	Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2015, 126, 2743-2743.	1.4	4
499	Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 2744-2744.	1.4	8
500	A Multicenter, Case-Control Study Evaluating the Characteristics and Outcome of ITP Patients Refractory to, Rituximab, Splenectomy and Both TPO Receptor Agonists. <i>Blood</i> , 2015, 126, 3460-3460.	1.4	2
501	Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study. <i>Blood</i> , 2015, 126, 517-517.	1.4	2
502	Randomized Phase III Study Comparing an Early PET Driven Treatment De-Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study. <i>Blood</i> , 2015, 126, 577-577.	1.4	43
503	Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients. <i>Blood</i> , 2015, 126, 816-816.	1.4	5
504	Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199), Tj ETQq0 0 0 rgBT /Overlock 1 Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 829-829.	1.4	6

#	ARTICLE	IF	CITATIONS
505	A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL).. Journal of Clinical Oncology, 2015, 33, 3065-3065.	1.6	21
506	Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level.. Journal of Clinical Oncology, 2015, 33, 8503-8503.	1.6	15
507	Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression-free survival (PFS) in first-line follicular lymphoma (FL) studies: Results from the prospectively specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) analysis with individual patient data (IPD) of 3.837 patients (pts).. Journal of Clinical Oncology, 2015, 33, 8504-8504.	1.6	14
508	Abstract 4810: Exome sequencing of refractory diffuse large B-cell lymphomas highlights candidate genes for targeted resequencing. , 2015, , .		0
509	Impact of 18 f-Fluoro-Deoxyglucose Positron Emission Tomography Imaging in the Management of Mantle Cell Lymphoma. Blood, 2015, 126, 3951-3951.	1.4	0
510	Inhibition of Hedgehog Signaling for the Treatment of Lymphoma and CLL: A Phase II Study from the Lysa. Blood, 2015, 126, 3970-3970.	1.4	0
511	Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study. Blood, 2015, 126, 1472-1472.	1.4	0
512	Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor Burden Follicular Lymphoma. A Pooled Analysis of Three Multicenter Studies. Blood, 2015, 126, 3919-3919.	1.4	0
513	Prevalence and Prognostic Value of BCL2 and MYC Protein Expression within ABC and GCB Subtypes in Patients with Previously Untreated, Diffuse Large B-Cell Lymphoma: Analysis from the Phase III MAIN Study. Blood, 2015, 126, 3971-3971.	1.4	0
514	Idelalisib Treatment Is Associated with Improved Cytopenias in Patients with Relapsed/Refractory iNHL and CLL. Blood, 2015, 126, 1747-1747.	1.4	0
515	Obinutuzumab for chronic lymphocytic leukemia. Expert Review of Hematology, 2014, 7, 533-543.	2.2	8
516	Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leukemia and Lymphoma, 2014, 55, 1854-1860.	1.3	83
517	Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma. Blood, 2014, 123, 2740-2742.	1.4	11
518	Young Patients With Nonâ€“Germinal Center B-Cellâ€“Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B. Journal of Clinical Oncology, 2014, 32, 3996-4003.	1.6	79
519	Central nervous system involvement in chronic lymphocytic leukemia: uncommon manifestation with undefined therapeutic management. Leukemia and Lymphoma, 2014, 55, 1939-1941.	1.3	9
520	PET-CT and diagnostic CT: The synergy of metabolic and morphological data in onco-haematology. Diagnostic and Interventional Imaging, 2014, 95, 55-62.	3.2	8
521	Development of model for analysing respective collections of intended hematopoietic stem cells and harvests of unintended mature cells in apheresis for autologous hematopoietic stem cell collection. Transfusion and Apheresis Science, 2014, 50, 294-302.	1.0	0
522	PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 408-415.	6.4	39

#	ARTICLE	IF	CITATIONS
523	PI3K $\gamma$ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. <i>New England Journal of Medicine</i> , 2014, 370, 1008-1018.	27.0	956
524	Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant <i>Erwinia chrysanthemi</i> -derived L-asparaginase. <i>Investigational New Drugs</i> , 2014, 32, 795-805.	2.6	28
525	Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis. <i>British Journal of Haematology</i> , 2014, 164, 659-667.	2.5	31
526	High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 664-670.	2.4	123
527	Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. <i>Lancet Haematology</i> , 2014, 1, e17-e27.	4.6	138
528	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	21.4	147
529	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471.	6.2	96
530	Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?. <i>Clinical Cancer Research</i> , 2014, 20, 5226-5239.	7.0	17
531	t(14;18) Translocation: A Predictive Blood Biomarker for Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1347-1355.	1.6	115
532	Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis. <i>Human Pathology</i> , 2014, 45, 2085-2093.	2.0	23
533	Administration of Anticancer Drugs: Exposure in Hospital Nurses. <i>Clinical Therapeutics</i> , 2014, 36, 401-407.	2.5	14
534	Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 1066-1073.	1.6	304
535	The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2014, 99, 715-725.	3.5	52
536	Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. <i>Blood</i> , 2014, 124, 3228-3236.	1.4	142
537	A restricted IGHV gene repertoire in splenic marginal zone lymphoma is associated with autoimmune disorders. <i>Haematologica</i> , 2014, 99, e197-e198.	3.5	18
538	The Lymphoid Variant of Hypereosinophilic Syndrome. <i>Medicine (United States)</i> , 2014, 93, 255-266.	1.0	98
539	Abstract LB-272: Genome-wide association study identifies multiple susceptibility loci for diffuse large B-cell lymphoma. <i>Cancer Research</i> , 2014, 74, LB-272-LB-272.	0.9	4
540	Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study. <i>Blood</i> , 2014, 124, 146-146.	1.4	19

#	ARTICLE	IF	CITATIONS
541	Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study. <i>Blood</i> , 2014, 124, 1625-1625.	1.4	1
542	Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2014, 124, 1708-1708.	1.4	10
543	An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma. <i>Blood</i> , 2014, 124, 1718-1718.	1.4	10
544	Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 3067-3067.	1.4	15
545	Tumoral Maximum Standardized Uptake Value > 10 Measured on 18 f-FDG-PET: A New Valid Marker to Discriminate Richter Syndrome. <i>Blood</i> , 2014, 124, 3306-3306.	1.4	1
546	The Bruton's Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL). <i>Blood</i> , 2014, 124, 3328-3328.	1.4	7
547	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies. <i>Blood</i> , 2014, 124, 4417-4417.	1.4	7
548	Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 4457-4457.	1.4	26
549	A Phase Ib Study of Obinutuzumab Combined with Lenalidomide for Relapsed/Refractory Follicular B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 4458-4458.	1.4	8
550	Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR). <i>Blood</i> , 2014, 124, 4674-4674.	1.4	4
551	Asparagine Synthetase Expression and L-Asparaginase Sensitivity in Aggressive Lymphomas. <i>Blood</i> , 2014, 124, 5494-5494.	1.4	1
552	A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Relapsed/Refractory DLBCL. <i>Blood</i> , 2014, 124, 628-628.	1.4	18
553	Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8519-8519.	1.6	16
554	The Bruton's tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8553-8553.	1.6	5
555	Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, e19554-e19554.	1.6	3
556	A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8620-TPS8620.	1.6	1
557	Prognostic value of PET-CT after frontline therapy in follicular lymphoma: A pooled analysis of central review in three multicenter studies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8502-8502.	1.6	0
558	Meta-analysis of the risk of secondary neoplasm in patients treated for non-Hodgkin lymphoma with rituximab.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19541-e19541.	1.6	0



#	ARTICLE	IF	CITATIONS
559	Individual Patient Data (IPD) Meta-Analysis of Rituximab Maintenance (MR) for Patients (pts) with Follicular Lymphoma (FL). <i>Blood</i> , 2014, 124, 4462-4462.	1.4	0
560	A New Prognostic Score for Patients Older Than 60 Years with a Classical Hodgkin Lymphoma: A Retrospective Analysis on 165 Patients. <i>Blood</i> , 2014, 124, 1721-1721.	1.4	0
561	High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study. <i>Blood</i> , 2014, 124, 2526-2526.	1.4	2
562	Pediatric ALL-like Therapy in Adults with T-Cell Lymphoblastic Lymphoma: Results of the Graall-Lysa LL03 Study. <i>Blood</i> , 2014, 124, 371-371.	1.4	1
563	Identification of Previously Unrecognized CD1d-Restricted Peripheral T Cell Lymphomas (PTCLs) in Mouse and Human Reveals Blocking Anti-CD1d Monoclonal Antibodies As a New Therapeutic Possibility in PTCLs. <i>Blood</i> , 2014, 124, 4485-4485.	1.4	0
564	Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study. <i>Blood</i> , 2014, 124, 4430-4430.	1.4	0
565	No Increased Risk of Secondary Neoplasms in Patients Treated with Rituximab for Non-Hodgkinâ€™s Lymphoma : A Meta-Analysis of 9 Trials. <i>Blood</i> , 2014, 124, 1659-1659.	1.4	4
566	Long-Term Remission (>3 years) after Rituximab Monotherapy Used for Patients with Relapsed Indolent Non-Hodgkin Lymphomas (NHL). <i>Blood</i> , 2014, 124, 1709-1709.	1.4	0
567	Impact of rituximab on stem cell mobilization following ACVBP regimen in poorâ€™risk patients with diffuse large Bâ€™cell lymphoma: results from a large cohort of patients. <i>Transfusion</i> , 2013, 53, 115-122.	1.6	4
568	Pretreatment Levels of Vascular Endothelial Growth Factor in Plasma Predict a Complete Remission Rate and Time to Relapse or Progression in Patients with Diffuse Large B-Cell Lymphoma. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2013, 61, 165-174.	2.3	2
569	First immunochemotherapy outcomes in elderly patients with CLL: A retrospective analysis. <i>Journal of Geriatric Oncology</i> , 2013, 4, 141-147.	1.0	11
570	Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2920-2926.	1.6	137
571	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 525-533.	10.7	257
572	Pregnancy and multiple myeloma are not antinomic. <i>Leukemia and Lymphoma</i> , 2013, 54, 2738-2741.	1.3	9
573	Treatment approaches to asymptomatic follicular lymphoma. <i>Expert Review of Hematology</i> , 2013, 6, 747-758.	2.2	0
574	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	1.2	193
575	Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts. <i>Cytokine</i> , 2013, 64, 523-531.	3.2	16
576	Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1898-1907.	1.3	36

#	ARTICLE	IF	CITATIONS
577	CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. <i>Blood</i> , 2013, 121, 48-53.	1.4	243
578	Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. <i>Haematologica</i> , 2013, 98, 1107-1114.	3.5	70
579	Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. <i>Haematologica</i> , 2013, 98, 1726-1731.	3.5	131
580	Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. <i>Annals of Oncology</i> , 2013, 24, 2612-2618.	1.2	30
581	<sup>90</sup> Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1977-1983.	1.6	192
582	Improving Cancer Patient Care with Combined Medication Error Reviews and Morbidity and Mortality Conferences. <i>Chemotherapy</i> , 2013, 59, 330-337.	1.6	8
583	Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, <i>IGHV</i> mutations, and survival. A study of 76 cases. <i>Histopathology</i> , 2013, 62, 876-893.	2.9	12
584	Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2912-2919.	1.6	185
585	Monitoring NK cell activity in patients with hematological malignancies. <i>Oncolimmunology</i> , 2013, 2, e26011.	4.6	40
586	Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. <i>Leukemia</i> , 2013, 27, 252-255.	7.2	42
587	Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial. <i>Leukemia</i> , 2013, 27, 2102-2105.	7.2	4
588	Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. <i>Blood</i> , 2013, 121, 2529-2532.	1.4	70
589	Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). <i>Blood</i> , 2013, 122, 1137-1143.	1.4	120
590	Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. <i>Haematologica</i> , 2013, 98, 1014-1021.	3.5	98
591	Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. <i>Haematologica</i> , 2013, 98, 357-363.	3.5	51
592	Lenalidomide In Combination With R-CHOP (R2-CHOP) In Patients With High Burden Follicular Lymphoma: Phase 2 Study. <i>Blood</i> , 2013, 122, 248-248.	1.4	6
593	Role Of High-Dose Cytarabine and Total Body Irradiation Conditioning before Autologous Stem Cell Transplantation In Mantle Cell Lymphoma - A Comparison Of Nordic MCL2, HOVON 45, and European MCL Younger Trials. <i>Blood</i> , 2013, 122, 3367-3367.	1.4	6
594	A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 4397-4397.	1.4	9

#	ARTICLE	IF	CITATIONS
595	Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy. <i>Blood</i> , 2013, 122, 509-509.	1.4	66
596	Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study. <i>Blood</i> , 2013, 122, 764-764.	1.4	8
597	Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2013, 122, 85-85.	1.4	10
598	An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS8614-TPS8614.	1.6	2
599	Follicular Lymphoma. , 2013, , 143-156.		1
600	Abstract 4055: Non-canonical telomere maintenance mechanism in B-cell chronic lymphocytic leukemia.. , 2013, , .		0
601	Iron Parameters and Relation To Prognosis In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study. <i>Blood</i> , 2013, 122, 2202-2202.	1.4	0
602	Obinutuzumab (GA101) Plus CHOP Or FC In Relapsed/Refractory Follicular Lymphoma: Final Data From The Maintenance Phase Of The Phase 1b GAUDI Study (BO21000). <i>Blood</i> , 2013, 122, 1814-1814.	1.4	0
603	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. <i>Blood</i> , 2013, 122, 76-76.	1.4	1
604	Toll-Like Receptor Profiles In Splenic Marginal Zone B-Cell Lymphoma and Splenic Diffuse Red Pulp B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 3009-3009.	1.4	0
605	Prognostic Value Of Red Blood Cell and Platelet Transfusion In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study. <i>Blood</i> , 2013, 122, 3663-3663.	1.4	0
606	Circulating t(14;18)+ Cells As Predictive Markers Of Follicular Lymphoma Development. <i>Blood</i> , 2013, 122, 364-364.	1.4	0
607	Reappraisal Of The p16INK4A/Prb Pathway and Telomerase Activity, Markers Of Cell Activation and Aging, In Adult Acute Lymphoblastic Leukemia: A Graall Study. <i>Blood</i> , 2013, 122, 2579-2579.	1.4	0
608	A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. <i>Annals of Oncology</i> , 2012, 23, 2687-2695.	1.2	23
609	Sequential combination of high dose methotrexate and <sc> </sc>-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+/CD56+ hematodermic neoplasm. <i>Leukemia and Lymphoma</i> , 2012, 53, 1633-1637.	1.3	23
610	Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. <i>Blood</i> , 2012, 119, 5126-5132.	1.4	175
611	Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. <i>Blood</i> , 2012, 120, 2650-2657.	1.4	56
612	Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. <i>Haematologica</i> , 2012, 97, 1594-1602.	3.5	76

#	ARTICLE	IF	CITATIONS
613	CNS prophylaxis in diffuse large B-cell lymphoma – Authors' reply. <i>Lancet, The</i> , 2012, 379, 1486-1487.	13.7	0
614	Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20 <sup>+</sup> Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 4462-4469.	1.6	248
615	Δu-Calpain Conversion of Antiapoptotic Bfl-1 (BCL2A1) into a Prodeath Factor Reveals Two Distinct alpha-Helices Inducing Mitochondria-Mediated Apoptosis. <i>PLoS ONE</i> , 2012, 7, e38620.	2.5	18
616	Impact of [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High-Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. <i>Journal of Clinical Oncology</i> , 2012, 30, 4317-4322.	1.6	168
617	Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. <i>Lancet Oncology, The</i> , 2012, 13, 196-206.	10.7	349
618	Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. <i>Annals of Oncology</i> , 2012, 23, 2380-2385.	1.2	48
619	Predictors of prescription errors involving anticancer chemotherapy agents. <i>European Journal of Cancer</i> , 2012, 48, 1192-1199.	2.8	29
620	Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2012, 5, 27.	17.0	29
621	Current and future management of follicular lymphoma. <i>International Journal of Hematology</i> , 2012, 96, 544-551.	1.6	21
622	MicroRNA expression profile in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , 2012, 156, 279-281.	2.5	35
623	In non-follicular lymphoproliferative disorders, <i>IGH</i> fusion is not restricted to chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2012, 158, 489-498.	2.5	26
624	Expression of MYC, IgM, As Well As Non-Germinal Centre B-Cell Like Immunophenotype and Positive Immunofish Index Predict a Worse Progression Free Survival and Overall Survival in a Series of 670 De Novo Diffuse Large B-Cell Lymphomas Included in Clinical Trials: A GELA Study of the 2003 Program. <i>Blood</i> , 2012, 120, 1539-1539.	1.4	1
625	Anti-Leukemic Activity of a Novel Pegylated Recombinant Erwinia Chrysanthemi-Derived L-Asparaginase On Lymphoid Cell Lines and Leukemia-Bearing Mouse Models.. <i>Blood</i> , 2012, 120, 2571-2571.	1.4	2
626	Early Stage Follicular Lymphoma: Is There a Clinical Impact of First Line Treatment?. <i>Blood</i> , 2012, 120, 2722-2722.	1.4	1
627	Mechanisms of Telomere Maintenance Dysfunction in B-Chronic Lymphocytic Leukemia Through CpG Island Methylation. <i>Blood</i> , 2012, 120, 3489-3489.	1.4	1
628	Integrated Analysis of High-Resolution Gene Expression and Copy Number Profiling Identified Biallelic Deletion of CDKN2A/2B Tumor Suppressor Locus As the Most Frequent and Unique Genomic Abnormality in Diffuse Large B-Cell Lymphoma (DLBCL) with Strong Prognostic Value in Both GCB and ABC Subtypes and Not Overcome by a Dose-Intensive Immunochemotherapy Regimen Plus Rituximab. Results of a Prospective GELA Clinical Trial Program. <i>Blood</i> , 2012, 120, 415-415.	1.4	6
629	MYC Gene Simple Hit Is a Strong Independent Predictive Factor of Survival in Diffuse Large B-Cell Lymphomas in Contrast to MYC Double-Hit Gene Alterations: A Study by the Groupe d'Etude Des Lymphomes De l'Adulte. <i>Blood</i> , 2012, 120, 541-541.	1.4	3
630	A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2012, 120, 56-56.	1.4	11

#	ARTICLE	IF	CITATIONS
631	Addition of Rituximab Improves Outcome of HIV Negative Patients with Burkitt Lymphoma Treated with the Lmba Protocol: Results of the Randomized Intergroup (GRAALL-Lysa) LMBA02 Protocol. (IGR) Tj ETQq1 1 0.7843.14 rgBT /Qverlock	1.4	0
632	High DNA Methyltransferase DNMT3B Levels: A Poor Prognostic Marker in Acute Myeloid Leukemia. PLoS ONE, 2012, 7, e51527.	2.5	58
633	What Is the Best First-Line Treatment Strategy for Patients with Indolent Lymphomas?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 488-493.	3.8	3
634	Single Nucleotide Polymorphisms in ABCB1 and CBR1 Predict Toxicity to R-CHOP Type Regimens in Patients with Diffuse Non Hodgkin's Lymphoma. Blood, 2012, 120, 1616-1616.	1.4	0
635	Abexinostat (S78454/PCI-24781), an Oral Pan-Histone Deacetylase (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I Dose-Escalation Study in 35 Patients. Blood, 2012, 120, 3643-3643.	1.4	2
636	P53 Prevents TCR-Dependent Peripheral T-Cell Lymphomagenesis From Chronically Stimulated T Cells.. Blood, 2012, 120, 2401-2401.	1.4	0
637	Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose Therapy with Stem-Cell Transplantation in Poor Risk Patients with Diffuse Large B-Cell Lymphoma. Blood, 2012, 120, 812-812.	1.4	11
638	Lymphoma Occurring Over the Age of 90: Clinical Presentation and Outcome. Blood, 2012, 120, 1582-1582.	1.4	0
639	Absence of Prognostic Impact Associated with the Use of Statins in Patients with Follicular Lymphoma in the Rituximab Era: An Exploratory Analysis From the PRIMA Study.. Blood, 2012, 120, 2649-2649.	1.4	0
640	Impact of Reduced Dose Intensity for Elderly Patients with Diffuse Large B-CELL Lymphoma Receiving R-CHOP Every 14 or 21 Days: An Analysis of the LNH03-6B GELA Study.. Blood, 2012, 120, 2723-2723.	1.4	1
641	Detection of Leukemic Phase in Patients with Follicular Lymphoma At Diagnosis: A Rare Event Associated with Poor Prognosis. Blood, 2012, 120, 1594-1594.	1.4	2
642	Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATL): Final Analysis of a Retrospective Study On the Behalf of Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).. Blood, 2012, 120, 3105-3105.	1.4	0
643	Expression of a Dysfunctional Activation Induced Cytidine Deaminase Is Correlated with Disease Progression in Splenic Marginal Zone Lymphoma.. Blood, 2012, 120, 2397-2397.	1.4	0
644	Low Serum Vitamin D Levels Are Associated with Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and Lysa Studies.. Blood, 2012, 120, 2712-2712.	1.4	0
645	Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies. Blood, 2012, 120, 3637-3637.	1.4	0
646	Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity. Discovery Medicine, 2012, 13, 253-65.	0.5	30
647	5.51 Is Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) in CLL Still Under Debate? A Population Matched Analysis Between Auto-HSCT and Rituximab-Fludarabine-Cyclophosphamide in First-Line CLL Patients. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S279-S280.	0.4	0
648	Early Steps of Follicular Lymphoma Pathogenesis. Advances in Immunology, 2011, 111, 1-46.	2.2	91

#	ARTICLE	IF	CITATIONS
649	Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 257-270.	1.7	11
650	Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. <i>Lancet, The</i> , 2011, 377, 42-51.	13.7	957
651	Rituximab maintenance therapy for follicular lymphoma – Authors' reply. <i>Lancet, The</i> , 2011, 377, 1151-1152.	13.7	3
652	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNHO3-2B): an open-label randomised phase 3 trial. <i>Lancet, The</i> , 2011, 378, 1858-1867.	13.7	311
653	Maintenance therapy in follicular lymphoma. <i>Current Opinion in Oncology</i> , 2011, 23, 449-454.	2.4	2
654	Is There a Role for Bortezomib Combinations in the Management of Patients With Follicular Lymphoma?. <i>Journal of Clinical Oncology</i> , 2011, 29, 3349-3350.	1.6	6
655	Splenic marginal zone B-cell lymphoma. <i>Current Opinion in Oncology</i> , 2011, 23, 441-448.	2.4	37
656	Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation. <i>Blood</i> , 2011, 118, 1316-1322.	1.4	47
657	Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. <i>Blood</i> , 2011, 117, 7070-7078.	1.4	168
658	Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. <i>Haematologica</i> , 2011, 96, 1136-1143.	3.5	84
659	Cyclin-dependent kinase 1 expression is inhibited by p16INK4a at the post-transcriptional level through the microRNA pathway. <i>Oncogene</i> , 2011, 30, 1880-1891.	5.9	51
660	Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. <i>BMC Cancer</i> , 2011, 11, 478.	2.6	84
661	Relevance of a scoring system including CD11c expression in the identification of splenic diffuse red pulp small B-cell lymphoma (SRPL). <i>Hematological Oncology</i> , 2011, 29, 47-51.	1.7	42
662	CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma. <i>Modern Pathology</i> , 2011, 24, 993-1003.	5.5	29
663	Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. <i>Haematologica</i> , 2011, 96, 1128-1135.	3.5	99
664	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2011, 22, vi59-vi63.	1.2	66
665	Suspicion of Drug-Drug Interaction between High-Dose Methotrexate and Proton Pump Inhibitors: A Case Report – Should the Practice Be Changed?. <i>Chemotherapy</i> , 2011, 57, 225-229.	1.6	18
666	Positron Emission Tomography – Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants. <i>Journal of Clinical Oncology</i> , 2011, 29, 3194-3200.	1.6	176

#	ARTICLE	IF	CITATIONS
667	Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1799-1806.	6.3	131
668	Phase I Study of Escalating Doses of Lenalidomide Combined with R-CHOP (R2-CHOP) for Front-Line Treatment of B-Cell Lymphomas. <i>Blood</i> , 2011, 118, 1632-1632.	1.4	13
669	R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2B. <i>Blood</i> , 2011, 118, 2632-2632.	1.4	5
670	Complete Remission After First-Line Radio Plus Chemotherapy Is Enough to Improve Survival in Extra Nodal NK/T Cell Lymphoma. <i>Blood</i> , 2011, 118, 2679-2679.	1.4	4
671	Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999). <i>Blood</i> , 2011, 118, 268-268.	1.4	3
672	Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000). <i>Blood</i> , 2011, 118, 270-270.	1.4	7
673	Significant Prognostic Impact of [18F]Fluorodeoxyglucose-PET Scan Performed During and At the End of Treatment with R-CHOP in High-Tumor Mass Follicular Lymphoma Patients: A GELA-GOELAMS Study. <i>Blood</i> , 2011, 118, 877-877.	1.4	2
674	Obinutuzumab. <i>Drugs of the Future</i> , 2011, 36, 657.	0.1	0
675	FCGR3A and FCGR2A Polymorphisms Do Not Affect Response and Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab and Chemotherapy. A Study Based on 554 Patients Included in GELA (Groupe d'Etude des Lymphomes de l'Adulte) Prospective Multicentric Study LNH2003. <i>Blood</i> , 2011, 118, 90-90.	1.4	0
676	Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLN-1 Trial. <i>Blood</i> , 2011, 118, 878-878.	1.4	0
677	MALT lymphomas: pathogenesis can drive treatment. <i>Oncology</i> , 2011, 25, 1134-42, 1147.	0.5	40
678	Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance. <i>Blood</i> , 2010, 115, 2420-2429.	1.4	67
679	The t(14;18)(q32;q21)/IGH-MALT1 translocation in MALT lymphomas contains templated nucleotide insertions and a major breakpoint region similar to follicular and mantle cell lymphoma. <i>Blood</i> , 2010, 115, 2214-2219.	1.4	28
680	Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. <i>Blood</i> , 2010, 116, 1092-1104.	1.4	122
681	Lentiviral vectors and transduction of human cancer B cells. <i>Blood</i> , 2010, 116, 498-500.	1.4	17
682	Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. <i>Blood</i> , 2010, 116, 4777-4782.	1.4	118
683	Plasma TNF- $\alpha$ and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic Index. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2010, 58, 131-141.	2.3	37
684	Hairy cell leukaemia: a variant and splenic red pulp lymphoma: a single entity?. <i>British Journal of Haematology</i> , 2010, 150, 113-115.	2.5	19

#	ARTICLE	IF	CITATIONS
685	Lymphoma Recurrence 5 Years or Later Following Diffuse Large B-Cell Lymphoma: Clinical Characteristics and Outcome. <i>Journal of Clinical Oncology</i> , 2010, 28, 2094-2100.	1.6	107
686	CLLD8/KMT1F Is a Lysine Methyltransferase That Is Important for Chromosome Segregation. <i>Journal of Biological Chemistry</i> , 2010, 285, 20234-20241.	3.4	68
687	Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study. <i>Leukemia and Lymphoma</i> , 2010, 51, 399-405.	1.3	19
688	Long-Term Follow-Up of Patients With Newly Diagnosed Follicular Lymphoma in the Prerituximab Era: Effect of Response Quality on Survival—A Study From the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2010, 28, 822-829.	1.6	63
689	CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases. <i>Haematologica</i> , 2010, 95, 604-612.	3.5	80
690	S-phase lengthening induced by p16INK4a overexpression in malignant cells with wild-type pRb and p53. <i>Cell Cycle</i> , 2010, 9, 3306-3316.	2.6	15
691	13 Diffuse large B-cell lymphoma. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 8-9.	2.2	0
692	Rituximab maintenance for the Treatment of patients with Follicular Lymphoma: Systematic Review and Meta-Analysis of Randomized Trials - 2010 Update.. <i>Blood</i> , 2010, 116, 1798-1798.	1.4	3
693	Pharmacokinetics of RO5072759 (GA101) In Patients with Relapsed/Refractory CD20+ Malignant Disease (Phase I/II Study BO20999). <i>Blood</i> , 2010, 116, 1833-1833.	1.4	1
694	Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients — First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL. <i>Blood</i> , 2010, 116, 2878-2878.	1.4	6
695	Comparison of Single Agent GA101 In Japanese and European Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) — Results From Two Phase I Studies. <i>Blood</i> , 2010, 116, 4921-4921.	1.4	1
696	90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients. <i>Blood</i> , 2010, 116, 594-594.	1.4	9
697	Result of FDG PET-CT Imaging After Immunochemotherapy Induction Is a Powerful and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: An Analysis From the PRIMA Study. <i>Blood</i> , 2010, 116, 855-855.	1.4	7
698	Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy.. <i>Journal of Clinical Oncology</i> , 2010, 28, 8004-8004.	1.6	38
699	Predictive value of FCGR3A genotype on response to rituximab induction and maintenance therapy (MT) in follicular non-Hodgkin's lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2010, 28, 8065-8065.	1.6	2
700	Cancer chemotherapeutic error in hospitalized patients: Attributable damages and extra costs.. <i>Journal of Clinical Oncology</i> , 2010, 28, e19529-e19529.	1.6	0
701	A phase I study of escalating doses of lenalidomide combined with R-CHOP (R2-CHOP) for front-line treatment of B-cell lymphomas.. <i>Journal of Clinical Oncology</i> , 2010, 28, TPS297-TPS297.	1.6	0
702	Ã‰chos de l'ASCO sur les lymphomes. <i>Hematologie</i> , 2010, 16, 281-283.	0.0	0



#	ARTICLE	IF	CITATIONS
703	Comparison of Clinical Characteristics, Plasma Cytokine Signature, Cytokine Gene Polymorphisms and Outcome Between EBV Positive and Negative Hodgkin Lymphoma: a Study of the Groupe Des Lymphomes De l'Adulte (GELA). <i>Blood</i> , 2010, 116, 3884-3884.	1.4	0
704	Cost Effectiveness Analysis of Rituximab Maintenance In Patients with Untreated High Tumour Burden Follicular Lymphoma After Response to Immunochemotherapy: A UK National Healthcare Services Perspective.. <i>Blood</i> , 2010, 116, 3833-3833.	1.4	2
705	Transcriptional Activation of hTERT, the Human Telomerase Reverse Transcriptase, by Nuclear Factor of Activated T Cells. <i>Journal of Biological Chemistry</i> , 2009, 284, 35725-35734.	3.4	35
706	Immuno-Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5573-5579.	1.6	113
707	Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. <i>Blood</i> , 2009, 114, 3173-3180.	1.4	82
708	Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma. <i>Cancer</i> , 2009, 115, 4540-4546.	4.1	51
709	The host-tumor interface in B-cell non-Hodgkin lymphoma: A new world to investigate. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 196-201.	2.3	6
710	Telomere uncapping during <i>in vitro</i> lymphocyte senescence. <i>Aging Cell</i> , 2009, 8, 52-64.	6.7	28
711	Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant lymphocyte proliferation. <i>Leukemia Research</i> , 2009, 33, 1217-1223.	0.8	48
712	Two new miR-16 targets: caprin-1 and HMGA1, proteins implicated in cell proliferation. <i>Biology of the Cell</i> , 2009, 101, 511-524.	2.0	71
713	Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. <i>Lancet Oncology</i> , The, 2009, 10, 1160-1170.	10.7	96
714	Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. <i>Blood</i> , 2009, 113, 3307-3313.	1.4	39
715	Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial.. <i>Blood</i> , 2009, 114, 100-100.	1.4	6
716	Phase I Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2009, 114, 1704-1704.	1.4	16
717	10 Years Follow-up of the GELA LNH98.5 Study, First Randomized Study Comparing R-CHOP to CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 3741-3741.	1.4	10
718	R-CHOP14 Compared to R-CHOP21 in Elderly Patients with Diffuse Large B-Cell Lymphoma: Results of the Interim Analysis of the LNH03-6B GELA Study.. <i>Blood</i> , 2009, 114, 406-406.	1.4	23
719	Lymphoma recurrence 5 years or more following diffuse large B-cell lymphoma: Clinical characteristics and outcome. <i>Journal of Clinical Oncology</i> , 2009, 27, 8562-8562.	1.6	0
720	Lenalidomide in Combination with Melphalan and Dexamethasone in Patients with Newly-Diagnosed Light-Chain (AL)-Amyloidosis: a Multicenter Phase I/II Dose Escalation Study.. <i>Blood</i> , 2009, 114, 427-427.	1.4	0

#	ARTICLE	IF	CITATIONS
721	Recurrent cerebral venous thrombosis revealing paraneoplastic angiitis in Hodgkin's lymphoma. <i>Journal of Neuro-Oncology</i> , 2008, 89, 195-198.	2.9	12
722	Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 855-863.	2.3	19
723	The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. <i>Leukemia</i> , 2008, 22, 1917-1924.	7.2	95
724	Asymptomatic bone marrow involvement in patients presenting with cutaneous marginal zone B-cell lymphoma. <i>British Journal of Dermatology</i> , 2008, 159, 498-500.	1.5	15
725	Epstein-Barr Virus-Induced Lymphoproliferative Disorder After Rituximab Combined with CHOP Therapy. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 356-358.	1.4	7
726	T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?. <i>Human Pathology</i> , 2008, 39, 194-200.	2.0	24
727	High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 440-446.	1.6	226
728	Prognostic Systems for Lymphomas. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 839-861.	2.2	12
729	Risk-Adapted Salvage Treatment With Single or Tandem Autologous Stem-Cell Transplantation for First Relapse/Refractory Hodgkin's Lymphoma: Results of the Prospective Multicenter H96 Trial by the GELA/SFGM Study Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 5980-5987.	1.6	137
730	Phase III Trial of Consolidation Therapy With Yttrium-90-labeled rituximab Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5156-5164.	1.6	431
731	Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. <i>Annals of Oncology</i> , 2008, 19, 560-565.	1.2	7
732	Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment. <i>Annals of Oncology</i> , 2008, 19, 1485-1487.	1.2	14
733	Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. <i>Annals of Oncology</i> , 2008, 19, 774-779.	1.2	120
734	Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?. <i>Blood</i> , 2008, 111, 2253-2260.	1.4	144
735	Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. <i>Blood</i> , 2008, 112, 4824-4831.	1.4	304
736	Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. <i>Blood</i> , 2008, 111, 2388-2391.	1.4	114
737	Characteristics of Refractory and Relapsing Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 2589-2589.	1.4	5
738	RCHOP and RDHAP Followed by Autologous Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL) : Final Results of a Phase II Study from the GELA. <i>Blood</i> , 2008, 112, 581-581.	1.4	13

#	ARTICLE	IF	CITATIONS
739	Autologous Stem Cell Transplantation (auto-SCT) as the Treatment of Choice for Follicular Lymphoma Patients in First Relapse: Final Analysis of the Outcome of 175 Patients Treated in the GELA/GOELAMS FL 2000 Study. <i>Blood</i> , 2008, 112, 773-773.	1.4	3
740	Major dispersion in etoposide systemic exposure in malignant lymphoma patients receiving BEAM high dose chemotherapy followed by ABMT: A multicentre study of the Groupe d'Études des Lymphomes de l'Adulte (GELA). <i>Journal of Clinical Oncology</i> , 2008, 26, 8537-8537.	1.6	0
741	Indolent Mantle Cell Lymphoma (MCL): A Retrospective Detailed Clinical and Morphological Analysis of 21 Patients, with Histological, Cytological, Cytogenetic, Interphase Genetic, Immunoglobulin Gene, and Gene Expression Profiling Analysis.. <i>Blood</i> , 2008, 112, 1780-1780.	1.4	3
742	Multiple Secondary Genetic Events Inducing Histologic Progression (HP) of Non-MALT Marginal Zone Lymphoma (MZL): An Integrated Genomic Analysis of Genome-Wide Copy-Number-Changes (CNC) and Transcriptomic Data.. <i>Blood</i> , 2008, 112, 1198-1198.	1.4	0
743	Gene Expression Profile Analysis According to Recurrent Gene Copy Number Abnormalities Defines a Diffuse Large B-Cell Lymphoma Subgroup Characterized by 9p21 Locus Deletion, Ribosome Machinery Deregulation and Poor Prognosis. A GELA Study. <i>Blood</i> , 2008, 112, 803-803.	1.4	0
744	Molecular Characterization of the T(14;18)(q32;q21) Involving the IGH Locus and the MALT1 Gene in MALT Lymphomas. <i>Blood</i> , 2008, 112, 4145-4145.	1.4	0
745	EARLY Interim FDG-PET Scan in Localised Hodgkin Lymphoma: Evaluation of Practice in 5 French Centers. <i>Blood</i> , 2008, 112, 4935-4935.	1.4	3
746	Mir-21 Is Over Expressed in Aggressive SMZL. <i>Blood</i> , 2008, 112, 624-624.	1.4	0
747	Clinical Features, Prognosis and Treatment of Follicular Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 216-225.	2.5	61
748	Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 2235-2238.	1.3	21
749	Peripheral blood natural killer cell count is associated with clinical outcome in patients with aPI 2â€³ diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2007, 18, 1209-1215.	1.2	86
750	Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients With Classical Hodgkin's Lymphoma: A Study From the Groupe d'Étude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2007, 25, 1732-1740.	1.6	108
751	Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applicationsâ€”A Study From the Lunenburg Lymphoma Biomarker Consortium. <i>Journal of Clinical Oncology</i> , 2007, 25, 805-812.	1.6	271
752	Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. <i>Haematologica</i> , 2007, 92, 1083-1090.	3.5	52
753	Angioimmunoblastic T-Cell Lymphoma. <i>Medicine (United States)</i> , 2007, 86, 282-292.	1.0	113
754	Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease. <i>New England Journal of Medicine</i> , 2007, 357, 1916-1927.	27.0	412
755	Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 500-507.	2.8	23
756	Improved reliability of lymphoma diagnostics via PCR-based clonality testing: â€” Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. <i>Leukemia</i> , 2007, 21, 201-206.	7.2	279

#	ARTICLE	IF	CITATIONS
757	Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. <i>Leukemia</i> , 2007, 21, 207-214.	7.2	292
758	Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. <i>Leukemia</i> , 2007, 21, 1824-1826.	7.2	60
759	Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome. <i>Tissue Antigens</i> , 2007, 71, 071029015950001-???	1.0	11
760	Detailed characterization of 7q deletions by multicolor banding (mBAND) in marginal zone cell lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 2007, 175, 159-165.	1.0	4
761	Health-Related Quality of Life in Patients with Advanced-Stage Follicular Lymphoma Receiving Consolidation with 90Y-Ibritumomab Tiuxetan (Zevalin®) of First Remission: Results from the Randomized Phase 3 First-Line Indolent Trial (FIT).. <i>Blood</i> , 2007, 110, 3319-3319.	1.4	4
762	Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - A New Standard in Therapy?.. <i>Blood</i> , 2007, 110, 390-390.	1.4	6
763	Germinal Center Phenotype Determined by Immunohistochemistry on Tissue Microarray Does Not Correlate with Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy in the Randomized Trial LNH98-5. A GELA Study.. <i>Blood</i> , 2007, 110, 51-51.	1.4	4
764	90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients.. <i>Blood</i> , 2007, 110, 643-643.	1.4	29
765	Rituximab Combined with Chemotherapy and Interferon in Follicular Lymphoma Patients: Final Analysis of the GELA-GOELAMS FL2000 Study with a 5-Year Follow-Up.. <i>Blood</i> , 2007, 110, 792-792.	1.4	13
766	The translocations t(6;18;11)(q24;q21;q21) and t(11;14;18)(q21;q32;q21) lead to a fusion of the API2 and MALT1 genes and occur in MALT lymphomas. <i>Haematologica</i> , 2007, 92, 405-409.	3.5	9
767	Identification of a novel e8/a4 BCR/ABL fusion transcript in a case of a transformed Sezary syndrome. <i>Haematologica</i> , 2007, 92, 1277-1278.	3.5	6
768	Effectiveness of epoetin beta 30,000 UI once weekly (QW) for treatment of anemia in solid tumor patients under chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 19588-19588.	1.6	0
769	Distinct Expression Patterns of microRNAs in Activated B Cell (ABC) and Germinal Center B (GC) Subtypes of Diffuse Large B Cell Lymphoma (DLBCL).. <i>Blood</i> , 2007, 110, 562-562.	1.4	0
770	Inherited cytokine response and risk of lymphoma. <i>Lancet Oncology</i> , The, 2006, 7, 3-4.	10.7	13
771	Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. <i>Blood</i> , 2006, 107, 3053-3057.	1.4	390
772	Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas. <i>Blood</i> , 2006, 108, 278-285.	1.4	53
773	Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). <i>Blood</i> , 2006, 108, 2540-2544.	1.4	230
774	Cytogenetic and Molecular Analysis of 12 Cases of Primary Cutaneous Marginal Zone Lymphomas. <i>American Journal of Dermatopathology</i> , 2006, 28, 287-292.	0.6	19

#	ARTICLE	IF	CITATIONS
775	A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. <i>Histopathology</i> , 2006, 48, 162-173.	2.9	97
776	Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma. <i>Leukemia</i> , 2006, 20, 296-303.	7.2	45
777	Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. <i>Oncogene</i> , 2006, 25, 1560-1570.	5.9	132
778	Clinicopathologic Characteristics and Outcome of Diffuse Large B-Cell Lymphomas Presenting With an Associated Low-Grade Component at Diagnosis. <i>Journal of Clinical Oncology</i> , 2006, 24, 5234-5241.	1.6	64
779	The Poor Prognosis Value of High Intra-Tumoral Macrophages Counts in Follicular Lymphoma Patients Requires Selection of Appropriate Cut-Off and Can Be Circumvented by Rituximab Therapy.. <i>Blood</i> , 2006, 108, 822-822.	1.4	6
780	Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). <i>Journal of Clinical Oncology</i> , 2006, 24, 7508-7508.	1.6	24
781	Long Term Efficacy of Rituximab in B-Cell Post Transplantation Lymphoproliferative Disorders (B-PTLD): Update of the Multicenter, Open Label, Phase II Trial (M39037 TRIAL).. <i>Blood</i> , 2006, 108, 2764-2764.	1.4	5
782	VH Gene Analysis in Splenic Marginal Zone Lymphoma Identifies Patients with Structurally Similar B Cell Receptors but Does Not Provide Prognostic Information.. <i>Blood</i> , 2006, 108, 2421-2421.	1.4	0
783	Pharmacogenetic Study in Hodgkin's Lymphomas, Impact of UGT1A1 on Prognosis.. <i>Blood</i> , 2006, 108, 2266-2266.	1.4	0
784	Efficacy and Safety of Once Weekly Epoetin Beta 30 000 IU in 691 Patients with Solid or Lymphoid Malignancies Receiving Chemotherapy: Results from the NAUTICA Study.. <i>Blood</i> , 2006, 108, 3758-3758.	1.4	0
785	Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. <i>European Cytokine Network</i> , 2006, 17, 60-6.	2.0	53
786	The expression of TCR-gamma delta/CD3 complex in neoplastic gamma delta T-cell. <i>Haematologica</i> , 2006, 91, 1717-9.	3.5	7
787	Prevalence of Anticentromere F Protein Autoantibodies in 347 Patients with Non-Hodgkin's Lymphoma. <i>Annals of the New York Academy of Sciences</i> , 2005, 1050, 319-326.	3.8	19
788	Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases. <i>Leukemia</i> , 2005, 19, 1818-1823.	7.2	54
789	Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. <i>Cancer</i> , 2005, 104, 1434-1441.	4.1	35
790	Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). <i>Annals of Oncology</i> , 2005, 16, 1675-1682.	1.2	144
791	Combined QT Interval and Voltage Criteria Improve Left Ventricular Hypertrophy Detection in Resistant Hypertension. <i>Hypertension</i> , 2005, 46, 1207-1212.	2.7	39
792	Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2005, 23, 4117-4126.	1.6	1,316

#	ARTICLE	IF	CITATIONS
793	Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. <i>Blood</i> , 2005, 105, 1851-1861.	1.4	778
794	Systemic mastocytosis: Predictable factors of poor prognosis present at the onset of the disease. <i>European Journal of Internal Medicine</i> , 2005, 16, 387-390.	2.2	4
795	Clinicopathologic Features of Waldenström's Macroglobulinemia and Marginal Zone Lymphoma: Are They Distinct or the Same Entity?. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 220-224.	2.1	50
796	Analysis of IgVH, BCL-6, PIM, RHO/TTF and PAX5 Mutational Status in Splenic and Nodal Marginal Zone B Cell Lymphoma Suggests a Particular B Cell Origin.. <i>Blood</i> , 2005, 106, 162-162.	1.4	3
797	Maintenance Alemtuzumab in Refractory B-Cell Chronic Lymphocytic Leukemia Patients: Updated Data.. <i>Blood</i> , 2005, 106, 5032-5032.	1.4	1
798	Single or Tandem Autologous Stem-Cell Transplantation Given According to Prognostic Factors at Relapse for Hodgkin Lymphoma.. <i>Blood</i> , 2005, 106, 2069-2069.	1.4	5
799	Gene Expression Profile Associated with Survival in Patients with Diffuse Large B-Cell Lymphoma Treated by Chemotherapy and Rituximab.. <i>Blood</i> , 2005, 106, 159-159.	1.4	1
800	Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. <i>Haematologica</i> , 2005, 90, 470-8.	3.5	67
801	Atypical cytogenetic presentation of t(11;14) in mantle cell lymphoma. <i>Haematologica</i> , 2005, 90, 1708-9.	3.5	11
802	Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. <i>The Hematology Journal</i> , 2004, 5, 467-471.	1.4	23
803	Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2004, 33, 921-923.	2.4	84
804	Allele-specific binding to the -308 single nucleotide polymorphism site in the tumour necrosis factor-alpha promoter. <i>International Journal of Immunogenetics</i> , 2004, 31, 15-19.	1.2	33
805	Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults. <i>Journal of Clinical Oncology</i> , 2004, 22, 1864-1871.	1.6	289
806	Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. <i>Blood</i> , 2004, 103, 3529-3534.	1.4	162
807	Maintenance Therapy with a Monthly Injection of Alemtuzumab Prolongs Response Duration in Patients with Refractory B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (B-CLL/SLL). <i>Leukemia and Lymphoma</i> , 2004, 45, 711-714.	1.3	29
808	Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1361-1365.	1.6	27
809	Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2004, 104, 1584-1586.	1.4	12
810	Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. <i>Blood</i> , 2004, 103, 2727-2737.	1.4	127

#	ARTICLE	IF	CITATIONS
811	Long Term Results of the GELA Study, R-CHOP vs. CHOP in Elderly Patients with Diffuse Large B-Cell Lymphoma.. Blood, 2004, 104, 1383-1383.	1.4	7
812	Molecular Profiling of Diffuse Large B-Cell Lymphoma Identifies Robust Subtypes Including One Characterized by Host Inflammatory Response.. Blood, 2004, 104, 25-25.	1.4	1
813	Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years.. Blood, 2004, 104, 585-585.	1.4	12
814	Factors Prognostic for Response and Event Free Survival and Treatment Related Toxicity in 306 Patients with Follicular or Mantle Cell Lymphoma Randomized to Single Agent Rituximab Given at the Standard or at a Prolonged Schedule.. Blood, 2004, 104, 588-588.	1.4	3
815	Rituximab Given after High Dose Therapy and Autologous Stem Cell Transplantation Induces Durable Clearance of Minimal Residual Disease in about Half of the Patients with Follicular Non Hodgkin's Lymphoma : 36 Months Results of a Multicenter Open Label Phase II Trial (M39012 Trial).. Blood, 2004, 104, 747-747.	1.4	5
816	Long Term Follow-Up Shows No Clinical Benefit for CD34+ Selection of Autologous Transplants Following Myeloablative Therapy in Patients with Newly Diagnosed Myeloma : An EBMT Phase III Randomized Study.. Blood, 2004, 104, 921-921.	1.4	2
817	CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): A pilot study from the GELA. Journal of Clinical Oncology, 2004, 22, 6529-6529.	1.6	1
818	MICROALBUMINURIA AND OTHER CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH RESISTANT HYPERTENSION. Journal of Hypertension, 2004, 22, S106.	0.5	0
819	PREDICTORS OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH RESISTANT HYPERTENSION. Journal of Hypertension, 2004, 22, S155.	0.5	0
820	CORRELATES OF QT-INTERVAL PARAMETERS IN PATIENTS WITH RESISTANT HYPERTENSION. Journal of Hypertension, 2004, 22, S151.	0.5	0
821	USEFULNESS OF QT-INTERVAL PARAMETERS FOR CARDIOVASCULAR RISK STRATIFICATION IN HYPERTENSIVE TYPE 2 DIABETIC PATIENTS. Journal of Hypertension, 2004, 22, S116.	0.5	0
822	In Vivo Purge with Rituximab before Harvest Does Not Alter the Graft nor the Hematologic Recovery after Transplant.. Blood, 2004, 104, 910-910.	1.4	0
823	Is Conventional Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) an Optimal Long-Term Strategy for Non Hodgkin Lymphomas: A Retrospective Study from 1987 to 2004.. Blood, 2004, 104, 3328-3328.	1.4	0
824	Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin's lymphoma. British Journal of Haematology, 2003, 123, 90-99.	2.5	51
825	Autoimmune thrombocytopenic purpura after autologous stem cell transplantation. Bone Marrow Transplantation, 2003, 32, 89-95.	2.4	38
826	Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncology, The, 2003, 4, 95-103.	10.7	161
827	Outcome in Relation to Treatment Modalities in 48 Patients with Localized Gastric MALT Lymphoma: A Retrospective Study of Patients Treated During 1976-2001. Leukemia and Lymphoma, 2003, 44, 257-262.	1.3	29
828	The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood, 2003, 102, 3871-3879.	1.4	793

#	ARTICLE	IF	CITATIONS
829	Cytogenetic and molecular delineation of a region of chromosome 3q commonly gained in marginal zone B-cell lymphoma. <i>Haematologica</i> , 2003, 88, 31-8.	3.5	39
830	p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. <i>Annals of Oncology</i> , 2002, 13, 1108-1115.	1.2	84
831	Epileptic seizures after autologous peripheral blood progenitor infusion in a patient treated with high-dose chemotherapy for myeloma. <i>Bone Marrow Transplantation</i> , 2002, 29, 544-544.	2.4	27
832	Comparison Study for Genotyping of a Single-Nucleotide Polymorphism in the Tumor Necrosis Factor Promoter Gene. <i>Diagnostic Molecular Pathology</i> , 2002, 11, 228-233.	2.1	4
833	Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc $\gamma$ R1IIa gene. <i>Blood</i> , 2002, 99, 754-758.	1.4	1,819
834	Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. <i>Blood</i> , 2002, 100, 3037-3040.	1.4	78
835	Intensive Salvage Therapy With High-Dose Chemotherapy for Patients With Advanced Hodgkin's Disease in Relapse or Failure After Initial Chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 467-475.	1.6	127
836	CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2002, 346, 235-242.	27.0	4,928
837	Treatment of Splenic Marginal Zone B-Cell Lymphoma: An Analysis of 81 Patients. <i>Clinical Lymphoma and Myeloma</i> , 2002, 3, 41-47.	2.1	148
838	Intensive Salvage Therapy With High-Dose Chemotherapy for Patients With Advanced Hodgkin's Disease in Relapse or Failure After Initial Chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 467-475.	1.6	165
839	Multifocal progressive leukoencephalopathy occurring after refractory anemia and multiple infectious disorders consecutive to severe lymphopenia. <i>Annals of Hematology</i> , 2002, 81, 340-342.	1.8	17
840	Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2002, 30, 769-775.	2.4	45
841	Identification and validation of seven genes, as potential markers, for the differential diagnosis of small B cell lymphomas (small lymphocytic lymphoma, marginal zone B cell lymphoma and mantle cell) Tj ETQq1 1 0.784314 igBT /Ov		
842	Primary Thyroid Lymphoma Is a Heterogeneous Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 105-111.	3.6	65
843	Tumor necrosis factor-alpha mRNA stability in human peripheral blood cells after lipopolysaccharide stimulation. <i>European Cytokine Network</i> , 2002, 13, 92-8.	2.0	10
844	Human $\hat{3}$ T Cells Express a Higher TCR/CD3 Complex Density Than $\hat{1}$ T Cells. <i>Clinical Immunology</i> , 2001, 98, 358-363.	3.2	28
845	Skin Lesions in Malignancy. <i>Journal of Clinical Oncology</i> , 2001, 19, 2100-2101.	1.6	15
846	The superoxide dismutase content in erythrocytes predicts short-term toxicity of high-dose cyclophosphamide. <i>British Journal of Haematology</i> , 2001, 112, 405-409.	2.5	28



#	ARTICLE	IF	CITATIONS
847	Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2001, 113, 772-778.	2.5	90
848	Higher LPS-stimulated TNF- $\alpha$ mRNA levels in peripheral blood mononuclear cells from non-Hodgkin's lymphoma patients. <i>Experimental Hematology</i> , 2001, 29, 330-338.	0.4	19
849	Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. <i>Blood</i> , 2001, 97, 101-106.	1.4	506
850	Tumor necrosis factor $\alpha$ release is a major biological event associated with rituximab treatment. <i>The Hematology Journal</i> , 2001, 2, 378-384.	1.4	88
851	Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin's Lymphoma: Final Analysis of the Prospective LNH87-2 Protocol A Groupe d'Etude des Lymphomes de l'Adulte Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 3025-3030.	1.6	400
852	A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors. <i>Leukemia</i> , 2000, 14, 2159-2165.	7.2	8
853	Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma. <i>Experimental Hematology</i> , 2000, 28, 858-870.	0.4	104
854	Expression of genes coding for the tumor necrosis factor and lymphotoxin ligand-receptor system in non-Hodgkin's lymphomas. <i>Cancer Immunology, Immunotherapy</i> , 2000, 49, 469-475.	4.2	20
855	Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. <i>Blood</i> , 2000, 95, 802-806.	1.4	484
856	Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. <i>Blood</i> , 2000, 95, 1950-1956.	1.4	279
857	Factors That Predict Chemotherapy-Induced Myelosuppression in Lymphoma Patients: Role of the Tumor Necrosis Factor Ligand-Receptor System. <i>Journal of Clinical Oncology</i> , 2000, 18, 325-325.	1.6	58
858	Prognostic significance of survivin expression in diffuse large B-cell lymphomas. <i>Blood</i> , 2000, 96, 1921-5.	1.4	268
859	International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: Report of the jury. <i>Annals of Oncology</i> , 1999, 10, 13-20.	1.2	24
860	International Consensus Conference on High-Dose Therapy With Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the Jury. <i>Journal of Clinical Oncology</i> , 1999, 17, 423-423.	1.6	237
861	Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). <i>Nature Genetics</i> , 1999, 22, 63-68.	21.4	356
862	Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: frequent occurrence of dicentric rearrangements and possible association with adverse outcome. <i>Leukemia</i> , 1999, 13, 460-468.	7.2	47
863	Profiles and prognostic values of LDH isoenzymes in patients with non-Hodgkin's lymphoma. <i>Leukemia</i> , 1999, 13, 811-817.	7.2	25
864	Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: analysis of 300 cases in a single institution. <i>Bone Marrow Transplantation</i> , 1999, 23, 1309-1315.	2.4	14

#	ARTICLE	IF	CITATIONS
865	Characterization of germinal center dendritic cells in follicular lymphoma. <i>Experimental Hematology</i> , 1999, 27, 1768-1775.	0.4	7
866	Distinct chromosome 3 abnormalities in persistent polyclonal B-cell lymphocytosis. , 1999, 26, 221-228.		24
867	Long term outcome of patients with hairy cell leukemia treated with pentostatin. , 1999, 85, 65-71.		50
868	Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 1999, 12, 151-169.	1.7	14
869	Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. <i>American Journal of Medicine</i> , 1999, 106, 191-197.	1.5	45
870	Modulation of Costimulatory Molecules on Follicular Lymphoma Cells by TNF and CD40. <i>Leukemia and Lymphoma</i> , 1999, 33, 331-341.	1.3	5
871	Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study. <i>Annals of Oncology</i> , 1999, 10, 1349-1354.	1.2	38
872	BCL10 : rôle ambigu dans la cascade apoptotique et la tumorigenèse.. <i>Medicine/Sciences</i> , 1999, 15, 1469.	0.2	0
873	Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma. <i>Bone Marrow Transplantation</i> , 1998, 21, 1037-1041.	2.4	21
874	Mantle cell lymphoma: a retrospective study of 121 cases. <i>Leukemia</i> , 1998, 12, 1281-1287.	7.2	182
875	Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. <i>British Journal of Cancer</i> , 1998, 77, 2357-2362.	6.4	58
876	Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. <i>British Journal of Haematology</i> , 1998, 103, 235-241.	2.5	144
877	CD40 regulation of death domains containing receptors and their ligands on lymphoma B cells. <i>British Journal of Haematology</i> , 1998, 103, 684-689.	2.5	12
878	A New Death Receptor 3 Isoform: Expression in Human Lymphoid Cell Lines and Non-Hodgkin's Lymphomas. <i>Biochemical and Biophysical Research Communications</i> , 1998, 242, 376-379.	2.1	18
879	The Tumor Necrosis Factor Signaling Complex: Choosing a Path Toward Cell Death or Cell Proliferation. <i>Leukemia and Lymphoma</i> , 1998, 29, 81-92.	1.3	36
880	Frequency and significance of anemia in non-Hodgkin's lymphoma patients. <i>Annals of Oncology</i> , 1998, 9, 1109-1115.	1.2	74
881	Histologic transformation in follicular lymphoma. <i>Annals of Oncology</i> , 1998, 9, 803-805.	1.2	8
882	High CD34+ Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation. <i>Blood</i> , 1998, 91, 3148-3155.	1.4	186

#	ARTICLE	IF	CITATIONS
883	Genetic Polymorphisms in the Tumor Necrosis Factor Locus Influence Non-Hodgkin's Lymphoma Outcome. <i>Blood</i> , 1998, 91, 3574-3581.	1.4	263
884	Genetic Polymorphisms in the Tumor Necrosis Factor Locus Influence Non-Hodgkin's Lymphoma Outcome. <i>Blood</i> , 1998, 91, 3574-3581.	1.4	4
885	High CD34+ Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation. <i>Blood</i> , 1998, 91, 3148-3155.	1.4	2
886	Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. <i>Annals of Oncology</i> , 1997, 8, 701-704.	1.2	57
887	Identification of Two Lymphotoxin Beta Isoforms Expressed in Human Lymphoid Cell Lines and Non-Hodgkin's Lymphomas. <i>Biochemical and Biophysical Research Communications</i> , 1997, 238, 273-276.	2.1	11
888	Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients.. <i>Journal of Clinical Oncology</i> , 1997, 15, 1624-1630.	1.6	373
889	Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.. <i>Journal of Clinical Oncology</i> , 1997, 15, 1587-1594.	1.6	283
890	Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.. <i>Journal of Clinical Oncology</i> , 1997, 15, 499-508.	1.6	103
891	Distribution of the cytogenetic abnormality +i(3)(q10) in persistent polyclonal B-cell lymphocytosis: a FICTION study in three cases. <i>British Journal of Haematology</i> , 1997, 99, 531-536.	2.5	27
892	Towards new prognostic factors in diffuse large cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1996, 7, 993-996.	1.2	3
893	ELEVATED CIRCULATING LEVELS OF TNF $\alpha$ AND ITS p55 SOLUBLE RECEPTOR ARE ASSOCIATED WITH AN ADVERSE PROGNOSIS IN LYMPHOMA PATIENTS. <i>British Journal of Haematology</i> , 1996, 93, 352-359.	2.5	97
894	Prognostic significance of bcl-2 protein expression in aggressive non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). <i>Blood</i> , 1996, 87, 265-272.	1.4	119
895	Hepatic angiosarcoma in a patient with essential thrombocythaemia and Budd-Chiari syndrome. <i>European Journal of Cancer</i> , 1995, 31, 423.	2.8	3
896	Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. <i>Blood</i> , 1995, 86, 3257-3262.	1.4	2
897	Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome. <i>Blood</i> , 1994, 83, 2829-2835.	1.4	130
898	Heterogeneity of acute lymphoblastic leukemia in HIV-seropositive patients. <i>Annals of Oncology</i> , 1994, 5, 437-440.	1.2	13
899	Inhibition of CD10/neutral endopeptidase 24.11 promotes B-cell reconstitution and maturation in vivo.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 7618-7622.	7.1	29
900	Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. <i>Blood</i> , 1993, 82, 3539-3547.	1.4	68

#	ARTICLE	IF	CITATIONS
901	Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. a study of the groupe d'etude des lymphomes agressifs. American Journal of Medicine, 1991, 90, 77-84.	1.5	129
902	Anaphylactoid reaction with bronchospasm following intravenous cyclophosphamide administration. Annals of Hematology, 1991, 62, 74-75.	1.8	17
903	Antiemetic activity of high-dose methylprednisolone associated with continuous-infusion metoclopramide and oral alprazolam during multiple-day chemotherapy. Cancer Chemotherapy and Pharmacology, 1991, 28, 77-79.	2.3	1
904	The detection of bone marrow involvement in small-cell lung cancer using magnetic resonance imaging.. Journal of Clinical Oncology, 1988, 6, 397-398.	1.6	7